FEBRUARY 28, 2023

CURRICULUM VITAE

LESLIE BETH GORDON, MD, PHD

Business Address:
Hasbro Children's Hospital
Department of Pediatrics
593 Eddy Street
Providence, RI 02903

Business Telephone: (401) 444-5648

Business Fax Number: (508) 543-0377

Electronic Mail Address: leslie_gordon@brown.edu

EDUCATION:

1982-1986 **Bachelor of Arts**, University of New Hampshire, Durham, NH
Major: Zoology
Senior Thesis: *A New Polarographic Technique for Measurement of Oxyhemoglobin Dissociation Curves* with John J. Sasner, PhD., Department of Zoology.

1990-1991 **Master of Science**, Brown University, Providence, RI
Thesis: *Comparison of Serum Antibody Responses to CNS and Systemically Administered Ovalbumin.* Advisor: Helen F. Cserr, Professor of Medical Science.

1990-1998 **MD/PhD Program**, Brown University School of Medicine, Providence, RI Achieved top-ranking category of *outstanding* in the medical program.
Doctor of Philosophy Thesis: *The Cytolytic Response to P511 Mastocytoma Tumor Growth in Mouse Brain*. Advisor: Paul M. Knopf, Charles A. and Helen B. Stuart, Professor in Medical Science.

POSTGRADUATE TRAINING:

6/98 – 11/98 **Pediatrics Internship**
Rhode Island Hospital
Brown University, Providence, RI

1999-2003 **Post-doctoral Position and Research Associate**
Department of Anatomy and Cellular Biology
Tufts University School of Medicine, Boston, MA
Advisor: Professor Bryan P. Toole, PhD.

POSTGRADUATE HONORS AND AWARDS:

1998 Women in Medicine Outstanding Academic Achievement Award; Brown University, Providence, RI.

2003 Gerontological Society of America; Honored for contribution to cloning of the Progeria gene and forward movement in Progeria research; Opening plenary award presentation by Drs. George

Martin and Richard Besdine, along with presentation by Leslie Gordon entitled, "Partnerships for Progress in Progeria Research," Nov 2003.

2006 Working Mother Magazine; "Working Mother of the Year," May 2006.

2007 Commencement Forum; The Charles O. Cooke, M.D. Distinguished Visiting Lecture; "Taking Progeria from Obscurity to the Cutting Edge: A Parent-Scientist's Perspective on Saving Children with a Premature Aging Disease,"
Brown University, Providence, RI, May 2007.

2013 Brown Medical Alumni Association Early Achievement Award; Awarded to an alumnus who has graduated within the last 15 years in recognition of either outstanding service to the Medical School or their local community, or a significant scientific or academic achievement, Providence, RI, May 2013.

2013 Rhode Island Monthly Magazine; "2013 Top Docs" Providence, RI, May 2013.

2013 Graduation Marshal; Aid to the Chief Marshal for Warren Alpert Medical School, Brown University, May 2013.

2014 Research!America; Paul G. Rogers Distinguished Organization Advocacy Award; Awarded to Dr. Leslie Gordon on behalf of The Progeria Research Foundation, Washington, DC, Mar 2014.

2014 Eleventh Annual Unsung Heroines of Massachusetts, Unsung Heroine, Boston, MA, May 2014.

ACADEMIC APPOINTMENTS:

1999-2003 **Instructor of Pediatrics (Research):**
Rhode Island Hospital-Brown Medical School
Department of Pediatrics
Providence, RI

2003-2005 **Research Assistant Professor**
Tufts University School of Medicine
Department of Anatomy and Cellular Biology
Boston, MA

2004-2008 **Assistant Professor of Pediatrics (Research)**
Rhode Island Hospital-Brown Medical School
Department of Pediatrics
Providence, RI

2003-2004 **Adjunct Professor**
Department of Graduate and Medical Sciences
Boston University
Boston, MA
Graduate Mentor, Reader Master's Thesis for Alice Abrahamian, **"Cardiovascular Disease in Progeria – Does it Mimic Aging?"**

2007-2015 **Lecturer on Anesthesia**
Harvard Medical School
Boston, MA

2008-2015 **Associate Professor of Pediatrics (Research)**
Department of Pediatrics
Rhode Island Hospital and Alpert Medical School of Brown University
Providence, RI

2013 – Present **Research Scientist**
Department of Pediatrics
Women & Infants Hospital
Providence, RI

2015-Present **Research Associate in Anesthesia**
Harvard Medical School
Boston, MA

2015-Present **Professor of Pediatrics (Research)**
Department of Pediatrics
Rhode Island Hospital and Alpert Medical School of Brown University
Providence, RI

HOSPITAL APPOINTMENTS:

2005-2007 **Visiting Scientist**
Laboratory of Francis Collins, MD, PhD
National Human Genome Research Institute, NIH
Bethesda, MD

2007 – Aug 2021 **Associate Professor – Medical Staff**
Department of Anesthesia
Boston Children's Hospital
Boston, MA

2013-Present **Research Scientist**
Department of Pediatrics
Women & Infants Hospital
Providence, RI

Aug 2021 – Present **Senior Staff Scientist – Associate Professor**
Department of Anesthesia
Boston Children's Hospital
Boston, MA

OTHER APPOINTMENTS:

1999 **Founder**
The Progeria Research Foundation, Inc.
Peabody, MA
http://progeriaresearch.org

1999-Present **Public Awareness Committee**
The Progeria Research Foundation
Peabody, MA
http://www.progeriaresearch.org/committees

1999-Present	**Medical Research Committee** The Progeria Research Foundation Peabody, MA http://www.progeriaresearch.org/committees
2002-Present	**Medical Director** The Progeria Research Foundation Peabody, MA http://www.progeriaresearch.org/officers-and-staff
2002-2005	**Executive Director**: The PRF Research Consortium The Progeria Research Foundation Peabody, MA http://www.progeriaresearch.org/officers-and-staff
2004-2006	**Contractor and Associate Investigator** National Human Genome Research Institute, NIH Bethesda, MD Natural History Study: "Clinical Investigations into Hutchinson-Gilford Progeria Syndrome," via the Intergovernmental Personnel Act
2005-2007	**Visiting Scientist** Laboratory of Francis Collins, MD, PhD National Human Genome Research Institute, NIH Bethesda, MD

NATIONAL AND INTERNATIONAL GRANT REVIEW ACTIVITIES:

1999–Present	Bi-annual Grant Review as Part of 8-member Medical Research Committee, The Progeria Research Foundation.
Jun 2009	OD09-003 Challenge Grant – Panel #10 (2 grants), The National Institutes of Health.
Jan 2010	AFM-Group MYOLOGIE- N°14622, Association Francaise Contre les Myopathies.
Dec 2011	Sparks Charity, Heron House, 10 Dean Farrar Street, London SW1H 0DX. www.sparks.org.uk

MEMBERSHIP IN SOCIETIES:

1991-1998	Society for Neuroscience, Washington, DC
1993-Present	Sigma Xi Honor Society
1994-1998	Northeast Immune Privilege and Regulation Society

PUBLICATIONS LIST:

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS:

1) **Gordon LB**, Peacocke M, Gilchrest, BA. Induction of c-fos but not c-myc in S-91 cells by melanization signals. *Journal of Dermatological Science*. 1992; 3, 35-41 . doi: 10.1016/0923-1811(92)90006-W.

2) **Gordon LB**, Knopf PM, Cserr HF. Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. *Journal of Neuroimmunology.* 1992; 40, 81-87. doi: 10.1016/0165-5728(92)90215-7.

3) **Gordon LB**, Nolan SC, Cserr HF, Knopf PM, Harling-Berg CJ. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. *The Journal of Immunology.*1997; 159, 2399-2408.

4) **Gordon LB**, Nolan SC, Ksander BK, Knopf PM, Harling-Berg CJ. Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation. *Journal of Neuroimmunology.*1998; 88, 77-84. doi: 10.1016/S0165-5728(98)00077-0.

5) Eriksson M, Brown WT, **Gordon LB**, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. *Nature.* 2003; 423, 293-298. doi: 10.1038/nature01629.

6) **Gordon LB**, Harten IA, Calabro A, Sugumaran G, Csoka AB, Stern R, Brown WT, Hascall V, Toole BP. Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome. *Human Genetics*. 2003; 113, 178-187. doi: 10.1007/s00439-003-0958.

7) Scaffidi P, **Gordon LB**, Misteli T. The cell nucleus and aging: tantalizing clues and hopeful promises. *PLOS Biology.* 2005; 3, e395.

8) Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, **Gordon LB**, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101, 8963-8968. doi: 10.1073/pnas.0402943101.

9) **Gordon LB**, Harten IA, Patti ME, Lichtenstein AH. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome. *The Journal of Pediatrics.*2005; 146, 336-341. Doi: 10.1016.j.jpeds.2004.10.064.

10) Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely K, **Gordon LB**, Der CJ, Cox AD, Collins FS. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. *Proceedings of the National Academy of Sciences of the United States of America.* 2005;102, 12879-12884.

11) McClintock D, **Gordon LB**, Djabali K. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody. *Proceedings of the National Academy of Sciences of the United States of America.*2006*;* Epub 103, 2154-2159.

12) Varga R, Eriksson M, Erdos M, Olive M, Harten I, Kolodgie F, Capell B, Cheng J, Faddah D, Perkins S, Avallone H, San H, Xuan Q, Ganesh S, **Gordon LB**, Virmani R, Wight T, Nabel E, Collins FS. Progressive vascular smooth muscle defects in a mouse model of Hutchinson-Gilford progeria syndrome. *Proceedings of the National Academy of Sciences of the United States of America.* 2006; Epub 103, 3250-3255. doi: 10.1073/pnas.0600012103.

13) Lemire JM, Patis C, **Gordon LB**, Sandy JD, Toole BP, Weiss AS. Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts. *Mechanisms of Ageing and Development*. 2006; 127, 660-669. doi: 10.1016/j.mad.2006.03.004.

14) **Gordon LB**, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW. Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. *Pediatrics.* 2007; 120, 824-833. doi: 10.1542/peds.2007-1357.

15) McClintock D, Ratner D, Lokuge M, Owens DM, **Gordon LB**, Collins FS, Djabali K. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. *PLOS ONE.* 2007; 2, e1269. doi: 10.1371/journal.pone.0001269.

16) Kieran MW, **Gordon LB**, Kleinman M. New Approaches to Progeria. State-Of-The-Art Review Article. *Pediatrics*. 2007; 120, 834-841. doi: 10.1542/peds.2007-1356.

17) Merideth MA, **Gordon LB**, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer C, Zalewski C, Kim J, Soloman B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO 3rd, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. *The New England Journal of Medicine.* 2008; 358, 592-604. doi: 10.1056/NEJMoa0706898.

18) **Gordon LB**, Harling-Berg CJ, Rothman FG. Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences.* 2008; 63, 777-787. doi: 10.1093/gerona/63.8.777.

19) Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, **Gordon LB**, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine.* 2008; 87, 70-86. doi: 10.1097/MD.0b013e31816bc604.

20) Domingo DL, Trujillo MI, Council SE, Merideth MA, **Gordon LB**, Wu T, Introne WJ, Gahl WA, Hart TC. Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. *Oral Diseases.* 2009; 15, 187-195. doi: 10.1111/j.1601-0825.2009.01521.

21) Marji J, O'Donoghue SI, McClintock D, Satagopam VP, Schneider R, Ratner D, Worman HJ, **Gordon LB**, Djabali K. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. *PLOS One.* 2010; 5, e11132. doi: 10.1371.

22) Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, Gerhard-Herman M, Machan JT, Kutys R, Virmani R, Collins FS, Wight TN, Nabel EG, **Gordon LB**. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. *Arteriosclerosis, Thrombosis, and Vascular Biology.* 2010; 30, 2301-2309. doi: 10.1161/ATVBAHA.110.209460.

23) Gordon CM, **Gordon LB**, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller D, Kieran MW. Hutchinson-Gilford Progeria is a skeletal dysplasia. *Journal of Bone and Mineral Research.* 2011; 26, 1670-1679. doi: 10.1002/jbmr.392.

24) Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, Wight TN, Toole BP, **Gordon LB**. Age-Dependent loss of MMP-3 in Hutchinson-Gilford Progeria Syndrome. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences.* 2011; 66, 1201-1207. doi: 10.1093/gerona/glr137.

25) Guardiani E, Zalewsi C, Brewer C, Merideth M, Introne W, Smith AC, **Gordon LB**, Gahl W, Kim HJ. Otologic and audiologic manifestations of Hutchinson-Gilford Progeria Syndrome. *Laryngoscope.* 2011; 212, 2250-2255. doi: 10.1002/lary.22151.

26) Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, **Gordon LB**. Mechanisms of Premature Vascular Aging in Children with Hutchinson-Gilford Progeria Syndrome. *Hypertension*. 2012; 59, 92-97. doi: 10.1161/HYPERTENSIONAHA.111.180919.

27) Wenzel V, Roedl D, Gabriel D, **Gordon LB**, Meenhard H, Schneider R, Ring J, Djabali, K. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. *Biology Open.* 2012; 1, 516-526. doi: 10.1242/bio.20121149.

28) Ulrich NJ, Silvera M, Campbell SE, **Gordon LB**. Craniofacial Abnormalities in Hutchinson-Gilford Progeria Syndrome. *American Journal of Neuroradiology.* 2012; 33, 1512-1518. doi: 10.3174/ajnr.A3088.

29) Cleveland RH**, Gordon LB**, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kiernan MW. A Prospective Study of Radiographic Manifestations in Hutchinson-Gilford Progeria Syndrome. *Pediatric Radiology.* 2012; 42, 1089-1098. doi: 10.1007/s00247-012-2423-1.

30) **Gordon LB**, Kleinman ME, Miller DT, Neuberg D, Giobbie-Hurder A, Gerhard-Herman M, Smoot L, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW. Clinical Trial of a Farnesyltransferase Inhibitor in Children with Hutchinson-Gilford Progeria Syndrome. *Proceedings of the National Academy of Sciences*. 2012; 109, 16666-16671. doi: 10.1073/pnas.1202529109.

31) **Gordon LB**, Cao K, Collins FS. Progeria: Translational Insights from Cell Biology. *The Journal of Cell Biology*. 2012; 199, 9-13. doi: 10.1083/jcb.201207072.

32) Silvera VM, **Gordon LB**, Orbach DB, Campbell S, Machan J, Ullrich NJ. Imaging Characteristics of Cerebrovascular Arteriopathy and Stroke in Hutchinson-Gilford Progeria Syndrome. *American Journal of Neuroradiology*. 2013; 34, 1091-1097. doi: 10.3174/ajnr.A3341.

33) Ullrich NJ, Kieran MW, Miller DT, **Gordon LB**, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman MD. Neurologic Characteristics in Children with Hutchinson-Gilford Progeria Syndrome Before and After Treatment with the Farnesyltransferase Inhibitor Lonafarnib. *Neurology.*2013; 81, 427-430. doi: 10.1212/WNL.0b013e31829d85c0.

34) Kieran MW, **Gordon LB**, Kleinman ME. The role of the farnesyltransferase inhibitor lonafarnib in the treatment of Progeria. *Expert Opinion on Orphan Drugs.* 2014; 2, 95-105 doi: 10.1517/13543784.2012.688950.

35) Rork JF, Huang JT, **Gordon LB**, Kleinman M, Kieran MW, Liang MG, Initial Cutaneous Manifestations of Hutchinson-Gilford Progeria Syndrome. *Pediatric Dermatology*. 2014; 31, 196-202. doi: 10.1111/pde.12284.

36) **Gordon LB**, Rothman FG, López-Otín C, Misteli T. Progeria: A Paradigm for Translational Medicine. *Cell.* 2014; 156, 400-407. doi: 10.1016/j.cell.2013.12.028.

37) **Gordon LB**, Massaro JM, D'Agostino RB Sr, Campbell SC, Joan Brazier J, Brown WT, Kleinman ME, Kieran MW, and the Progeria Clinical Trials Collaborative. Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome. *Circulation.* 2014; 130, 27-34. doi: 10.1161/CIRCULATIONAHA.113.008285.

38) Miyamoto M, Djabali K, **Gordon LB**. Atherosclerosis in Ancient Humans, Accelerated Aging Syndromes and Normal Aging: Is Lamin A Protein a Common Link? *Global Heart.* 2014; 9, 211-218. doi: 10.1016/j.gheart.2014.04.001.

39) Gordon A, **Gordon LB**. The Progeria Research Foundation: its remarkable journey from obscurity to treatment. *Expert Opinion on Orphan Drugs*. 2014; 2, 1187-1195. doi: 10.1517/21678707.2014.970172.

40) Gabriel D, Roedl D, **Gordon LB**, Djabali K. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts. *Aging Cell*. 2015; 1, 78-91. doi: 10.1111/acel.12300.

41) **Gordon LB**, Kieran MW, Kleinman ME, Misteli T. The decision-making process and criteria in selecting candidate drugs for progeria clinical trials. *EMBO Molecular Medicine.* 2016; 1-3. doi 10.15252/emmm.201606280.

42) **Gordon LB**, Kleinman ME, Massaro J, D'Agostino RB Sr, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. *Circulation*. 2016 Jul 12; 134(2):114-25. doi: 10.1161/CIRCULATIONAHA.116.022188.

43) Rivera-Torres J, Calvo CJ, Llach A, Guzmán-Martínez G, Caballero R, González-Gómez C, Jiménez-Borreguero LJ, Guadix JA, Osorio FG, López-Otín C, Herraiz-Martínez A, Cabello N, Vallmitjana A, Benítez R, **Gordon LB**, Jalife J, Pérez-Pomares JM, Tamargo J, Delpón E, Hove-Madsen L, Filgueiras-Rama D, Andrés V**.** Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. *Proceedings of the National Academy of Sciences*. 2016; Doi: 10.1073/pnas.1603754113.

44) Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, Larrieu D, Jackson SP, Collins FS, Glover TW, **Gordon LB**. A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome. *Journal of Medical Genetics.* 2016 Dec 5; doi: 10.1136/jmedgenet-2016-104295.

45) Gabriel D, **Gordon LB,** Djabali K. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype. *Public Library of Science (PLOS) One***.** 2016 Dec 29; 11(12):e0168988. doi: 10.1371/journal.pone.0168988.

46) Gabriel D, Shafry DD, **Gordon LB**, Djabali K. Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts. *Oncotarget.* 2017 Jul 18; 8(39):64809-64826. doi: 10.18632/oncotarget.19363. eCollection 2017 Sep 12.

47) Mantagos IS, Kleinman ME, Kieran MW, **Gordon LB**. Ophthalmologic Features of Progeria. *American Journal of Ophthalmology*. 2017 Oct; 182:126-132. doi: 10.1016/j.ajo.2017.07.020. Epub 2017 Jul 27.

48) Bassir, SB, Chase, II, **Gordon LB**, Kieran, MW, Kleinman, ME, Paster, BJ, Sonis A. Microbiome at Sites of Gingival Recession in Children with Hutchinson-Gilford Progeria Syndrome. *Journal of Periodontology*. 2018 Jun; doi: 10.1002/JPER.17-0351. [Epub ahead of print].

49) Greer, MM, Kleinman, ME, **Gordon, LB**, Massaro, J, D'Agostino, R, Baltrusaitis, K, Kieran, MW, Gordon, CM. Pubertal Progression in Female Adolescents with Progeria. *Journal of Pediatric and Adolescent Gynecology*. 2017 Dec 16; pii: S1083-3188(17)30520-X. doi: 10.1016/j.jpag.2017.12.005.

50) **Gordon LB**, Campbell S, Massaro JM, D'Agostino RB, Kleinman ME, Kieran MW, Moses MA. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with Lonafarnib**.** *Pediatric Research.* 2018 May; doi: 10.1038/pr.2018.9.

51) Prakash, A, **Gordon, LB,** Kleinman, ME, Gurary, EB, Massaro, J, D'Agostino, R, Kieran, MW, Gerhard-Herman, M, Smoot, L. Cardiac Abnormalities in Patients with Hutchinson-Gilford Progeria Syndrome. *JAMA Cardiology.* 2018 Apr; doi: 10.1001/jamacardio.2017.5235.

52) **Gordon, LB**, Shappell, H, Massaro, J, D'Agostino, RB, Brazier, J, Campbell, SE, Kleinman, ME, Kieran MW, Association of Lonafarnib Treatment vs No Treatment with Mortality Rate in Patients with Hutchinson-Gilford Progeria Syndrome, *JAMA*, 2018 Apr; doi:10.1001/jama.2018.3264.

53) Dubose, A, Lichtenstein, S, Petrash, N, Erdos, M, **Gordon, LB,** Collins, FS**.** Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts, *Proceedings of the National Academy of Sciences of the United States of America.* 2018 Apr 17; doi: 10.1073/pnas.1802811115.

54) Lessel D, Ozel A.B, Campbell S, Saad A, Arlt M, McSweeney KM, Plaiasu V, Szakszon K, Szőllős A, Rusu C, Rojas A, Lopez-Valdez J, Thiele H, Nurnberg P, Nickerson P, Bamshad M, Li J. Z, Kubisch C, Glover T, **Gordon LB.** Analyses of *LMNA*-negative juvenile progeroid cases confirms biallelic *POLR3A* mutations in Wiedemann–Rautenstrauch-like syndrome and expands the phenotypic spectrum of *PYCR1* mutations. *Human Genetics.* 2018; 137, 921-39. doi.org/10.1007/s00439-018-1957-1.

55) Gordon CM, Cleveland RH, Baltrusaitis K, Massaro J, D'Agostino RB, Liang MG, Snyder B, Walters M, Li X, Braddock DT, Kleinman ME, Kieran MW, **Gordon LB.** Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome. *Bone.* 2019; S8756-3282(19)30172-3 doi:10.1016/j.bone.2019.05.008.

56) Tsai A, Johnston P, **Gordon LB**, Walters M, Monica ME, Laor T. Skeletal Maturation and Long Bone Growth Patterns of Patients with Progeria: A Retrospective Study. *The Lancet Child & Adolescent Health*. 2020 Feb 28; doi.org/10/1016/S2352-4642(20)30023-7.

57) **Gordon LB**, To Succeed, Know Your Patients. *Cell*. *Voices.* 2020 APR 02; Volume 181, Issue 1, P19.; doi.org/10.1016/j.cell.2020.03.010.

58) Koblan LW, Erdos MR, Wilson C, Cabral WA, Levy JM, Iong, ZM, Tavarez UL, Davison L, Gete YG, Mao X, Newby GA, Doherty SP, Narisu N, Sheng Q, Krilow C, Lin CY, **Gordon** LB, Cao K, Collins FS, Brown JD, Liu DR. *In Vivo* Adenine Base Editing Rescues Hutchinson-Gilford Progeria Syndrome Nature. 2021 Jan 6. doi.org/10.1038/s41586-020-03086-7.

59) Erdos MR, Cabral WA, Narisu, Zerfas PM, Crumley S, Boku Y, Hanson G, Mourich DV, Kole R, Eckhaus MA, **Gordon LB,** Collins FS. A targeted antisense-based approach to inhibit progerin production demonstrates the i*n vivo* therapeutic potential of morpholinos for Hutchinson-Gilford progeria syndrome. Nature Medicine. 2021 Mar 11; doi: 10.1038/s41591-021-01274-0. Epub.

60) Puttaraju M, Jackson M, Klein S, Shilo A, Bennett CF, **Gordon** LB, Rigo F, Misteli T. Systematic screening identifies therapeutic antisense oligonucleotide candidates in Hutchinson Gilford Progeria Syndrome Nature Medicine. 2021 Mar 11; doi:10.1038/s41591-021-01262-4.

61) **Gordon LB,** Tuminelli K, Andrés V, Campisi J, Kieran MW, Doucette L, Gordon AS. The progeria research foundation 10th international scientific workshop; researching possibilities, ExTENding lives – webinar version scientific summary. Aging. 2021 Mar 17, Vol. 13; doi:10.18632/aging.202835.

62) Koblan L, Erdos M, **Gordon LB**, Collins F, Brown JD Liu DR. Base editor treats progeria in mice. Nature. 2021 Jun 18 doi:10.1038/d41586-021-011114-8

63) Lessel D, Rading K, Campbell S, Holger T, Altmüller J, **Gordon LB,**, Kubisch C. A novel homozygous synonymous variant further expands the phenotypic spectrum of *POLR3A*-related pathologies. American Journal of Medical Genetics Part A 2021 Oct 5 doi: 10.1002/ajmg.a.62525

64) LeClair J, Massaro J, Sverdlov O, **Gordon L,** Tripodis Y. Sample size determination for the association between longitudinal and time-to-event outcomes using the joint modeling time-dependent slopes parameterization. Stat Med. 2022 Dec 30;41(30):5810-5829. doi: 10.1002/sim.9595. Epub 2022 Oct 28

65) Díez-Díez M, Amorós-Pérez M, de la Barrera J., Vázquez E, Quintas A, A Pascual-Figal D, Dopazo A, Sánchez-ulCabo F, Kleinman M, **Gordon LB**, Fuster V, Andrés V, Fuster J. Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome. Geroscience. 2022 Jun 25. doi: 10.1007/s11357-022-00607-2

66) Malloy J, Berry D Correia A, Fragala-Pinkham, Coucci S, Riley S, Knight Pfaffinger J, Massaro J, Ehrbar R, D'Agostino R, Gurary E, **Gordon LB**, Kleinman M. Baseline Range of Motion, Strength, Motor Function, and Participation in Youth with Hutchinson-Gilford Progeria Syndrome. Boston, MA Jan 2023 DOI: 10.1080/01942638.2022.2158054

BOOKS, BOOK CHAPTERS:

1) **Gordon LB**. Progeria. *World Book Encyclopedia and Online Reference Center*. (eds Kilzer, NV and online) (World Book Publishing, 2007).

2) **Gordon LB**, Brown WT, Rothman FG. *LMNA* and the Hutchinson-Gilford Progeria Syndrome and Associated Laminopathies in *Inborn Errors of Development: The molecular basis of clinical disorders of morphogenesis, 2nd Edition* (eds Epstein CJ, Erickson RP, Wynshaw-Boris A) 1219-1229 (Oxford University Press, 2008).

3) **Gordon LB**. The Premature Aging Syndrome Hutchinson-Gilford Progeria Syndrome: Insights into Normal Aging in *Brocklehurst's Textbook of Geriatric Medicine and Gerontology*, 7th Edition (eds Fillit HM, Rockwood K, Woodhouse K) 66-72 (Saunders Elsevier, 2010).

4) **Gordon LB**. The Progeria Handbook: A guide for Families and Health Care providers of Children with Progeria; Executive Editor. (The Progeria Research Foundation, 2010).

5) **Gordon LB**. The Progeria Handbook: A guide for Families and Health Care providers of Children with Progeria (Spanish Edition); Executive Editor. (The Progeria Research Foundation, 2011).

6) **Gordon LB**. The Progeria Handbook: A guide for Families and Health Care providers of Children with Progeria (Portuguese Edition); Executive Editor. (The Progeria Research Foundation, 2012).

7) **Gordon LB**. Hutchinson-Gilford Progeria Syndrome in Neurocutaneous Syndromes section of the *Handbook of Clinical Neurology, 3rd Series* (eds Aminoff, MJ, Boller, F and Swaab, DF) (Saunders Elsevier, 2015).

8) **Gordon LB**. Progeria in *Nelson Textbook of Pediatrics, 20th Edition* (eds Kliegman RM, Stanton BF, St. Geme J, Schor N) (Saunders Elsevier, 2016).

9) **Gordon LB**, Brown WT, Rothman FG. *LMNA* and the Hutchinson-Gilford Progeria Syndrome and Associated Laminopathies in *Inborn Errors of Development: The Molecular Basis of Clinical Disorders of Morphogenesis, 3rd Edition* (eds Epstein CJ, Erickson RP, Wynshaw-Boris AJ) (Oxford University Press, 2016).

10) **Gordon LB**. The Premature Aging Syndrome Hutchinson-Gilford Progeria Syndrome: Insights into Normal Aging in *Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 8th Edition* (eds Fillit HM, Rockwood K, Young JB) (Saunders Elsevier, 2017).

11) **Gordon LB**. Progeria in *Nelson Textbook of Pediatrics, 21st Edition* (eds Kliegman RM, St. Geme J) (Elsevier, 2020).

12) **Gordon LB**. Progeria in *Nelson Textbook of Pediatrics, 22st Edition* (eds Kliegman RM, St. Geme J) (Elsevier, In Press).

13) **Gordon LB**. Progeria in *Brocklehurst Textbook of Geriatric Medicine & Gerontology, 9st Edition* (Pending).

NON-PEER-REVIEWED PUBLICATIONS:

1) **Gordon LB**. Our Premiere Issue! *The Progeria Research Foundation Newsletter.* (Jun 2001).

2) **Gordon LB**. Happy Holidays! *The Progeria Research Foundation Newsletter.* (Dec 2001).

3) **Gordon LB**. Welcome Summer! *The Progeria Research Foundation Newsletter.* (Jun 2002).

4) **Gordon LB**. Peace on Earth. *The Progeria Research Foundation Newsletter.* (Dec 2002).

5) **Gordon LB**. Summer is Here! *The Progeria Research Foundation Newsletter.* (Jul 2003).

6) **Gordon LB**. Happy New Year! *The Progeria Research Foundation Newsletter.* (Jan 2004).

7) **Gordon LB**. Summer 2004. *The Progeria Research Foundation Newsletter.* (2004).

8) **Gordon LB**. Winter 2005. *The Progeria Research Foundation Newsletter.* (2005).

9) **Gordon LB**. Summer/Fall 2005. *The Progeria Research Foundation Newsletter.* (2005).

10) **Gordon LB**. What a Year! *The Progeria Research Foundation Newsletter.* (Dec 2005).

11) **Gordon LB**. Paving the Way Toward a First-Ever Clinical Trial! *The Progeria Research Foundation Newsletter.* (Dec 2006).

12) **Gordon LB**. Progeria: Growing Old Too Fast. *Your World.* Print edition (2007).

Gordon LB. First Ever Progeria Clinical Drug Trial Has Begun! The *Progeria Research Foundation Newsletter.* (Aug 2007).

13) **Gordon LB**. 2007 Was an Amazing Year for PRF! *The Progeria Research Foundation Newsletter.* (Feb 2008).

14) **Gordon LB**. A Happy, Healthy New Year to All! *The Progeria Research Foundation Newsletter.* (Dec 2008).

15) **Gordon LB**. Moving Ahead at Lightning Speed. *The Progeria Research Foundation Newsletter.* (Aug 2009).

16) **Gordon LB**. Workshop Success! Ten Years Going Strong. *The Progeria Research Foundation Newsletter.* (May 2010).

17) **Gordon LB**. Groundbreaking Studies Identify New Potential Drug Treatment, Strengthen Progeria-Aging Link. *The Progeria Research Foundation Newsletter.* (Sep 2011).

18) **Gordon LB**. Special Edition: We Did It! *The Progeria Research Foundation Newsletter.* (Sep 2012).

19) **Gordon LB**. Recognizing Progeria: The Quest to Find Children With This Ultra Rare Aging Disease. *HealthNet News: FHI 360 - SATELLIFE* Issue #953 (Feb 2013).

20) **Gordon LB**. Triple Trial Enrollment Opens! *The Progeria Research Foundation Newsletter.* (Jul 2013).

21) **Gordon LB**. Fantastic News! Drugs Tested in PRF-Funded Clinical Trials Increase Estimated Lifespan of Children with Progeria. *The Progeria Research Foundation Newsletter.* (Jul 2014).

22) **Gordon LB**. Our Third Clinical Trial Begins! *The Progeria Research Foundation Newsletter.* (Sep 2015).

23) **Gordon LB**. 2-Drug Clinical Trial in Full Swing! *The Progeria Research Foundation Newsletter.* (Sep 2016).

24) **Gordon LB**. Phasae 1 Successful Phase 2 of 2-Drug Clinical Trial Begins! *The Progeria Research Foundation Newsletter.* (Sep 2017).

25) **Gordon LB**. Fantastic News! Study Published in JAMA Finds Treatment Extends Survival. *The Progeria Research Foundation Newsletter.* (Sep 2018).

26) **Gordon LB**. Lonafarnib Managed Access Program Launched! *The Progeria Research Foundation Newsletter.* (Sep 2019).

27) **Gordon LB**. The world has changed. Our mission has not. *The Progeria Research Foundation Newsletter.* (Sep 2020).

28) **Gordon LB**. First-ever Treatment for Progeria Receives FDA Approval! *The Progeria Research Foundation Newsletter.* (Sep 2021).

29) **Gordon LB**. PRF's 2-drug Clinical Trial Visits Complete; Monotherapy Trial Continues *The Progeria Research Foundation Newsletter.* (Sep 2022).

ABSTRACTS:

1) Peacocke M, Yaar M, Shaffer MA, **Gordon LB**, Gilchrest BA. Interferon and the epidermis: implications for cellular senescence. *Proceedings of the Workshop of Control of Cell Proliferation in Senescent Cells.* (1988).

2) Peacocke M, Yaar M, **Gordon LB**, Shaffer M, Gilchrest BA. Human melanocytes express high levels of c-fos messenger RNA when stimulated to differentiate. *Clinical Research.* 36, 683A (1989).

3) Peacocke M, **Gordon LB**, Shaffer MA, Gilchrest BA. Neurite outgrowth in human melanocytes is associated with high levels of neurofilament gene expression. *The Journal of Investigative Dermatology*. 92, 498 (1989).

4) **Gordon LB**, Peacocke M, Shaffer MA, Gilchrest BA. C-myc expression correlates with proliferative behavior and not differentiated function in S-91 melanoma cells. *The Journal of Investigative Dermatology*. 92, 436 (1989).

5) **Gordon LB**, Kahn M, Cserr HF, Knopf PM. Comparison of serum antibody responses to CNS and systemically administered ovalbumin. *Society for Neuroscience Abstract.* 16, 1209 (1990). Presented at the Society for Neuroscience National Meeting, Atlanta, GA, Nov 1990.

6) **Gordon LB**, Nolan SC, Knopf PM, Cserr HF. Influence of Th2-dominant CNS immunity on tumor growth in the brain. *Society for Neuroscience Abstract.* 20, 207 (1994). Presented at the Society for Neuroscience National Meeting, Miami Beach, FL, Nov 1994; The New England Association for Cancer Research, Providence, RI, Feb 1994; New England Immunology Regional Meeting, Woods Hole, MA, Oct 1994.

7) **Gordon LB**, Nolan SC, Cserr HF, Knopf PM. Brain-tumor-specific cellular immunity: afferent stimulation versus efferent inhibition. *The FASEB Journal.* 9, 6049 (1995). Presented at Experimental Biology National Meeting, Miami, FL, Apr 1995.

8) **Gordon LB**, Nolan SC, Harling-Berg CJ, Knopf PM. Normal cerebrospinal fluid inhibits development of tumor-specific CTL activity from Balb/c mouse splenocytes following tumor infusion into brain. *AAI Abstracts.* FASEB National Meeting, New Orleans, LA, Jun 1996.

9) Lemire JM, **Gordon LB**, Harten IA, Toole BP. Altered proteoglycan profiles in Hutchinson-Gilford Progeria. American Society for Matrix Biology Meeting, Houston, TX, Nov 2002.

10) Campbell SE, Laliberte L, Wolf-Jensen N, Hiris J, **Gordon LB**. Creating a Medical and Research Database for Hutchinson-Gilford Progeria Syndrome. Annual Public Health Research Day, Brown Medical School, Public Health Program, Providence, RI, April 2005.

11) Capell BC, Varga R, Erdos MR, Eriksson M, Madigan JP, Fiordalisi JJ, **Gordon LB**, Der CJ, Coz CJ, Collins FS. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome (2005). ASHG, Salt Lake City, UT, Oct 2005.

12) Rothman FG, Knopf PM, Hartan IA, **Gordon LB**. Pentraxin 3 (PTX 3) and Matrix Metal Proteinase 3 (MMP 3, Stromelysin 1) As Candidate Markers for Monitoring the Status of Progeria in Children with Hutchinson-Gilford Progeria Syndrome: *A Proposal*. The Progeria Research Foundation International Progeria Workshop, Boston, MA, Nov 2005.

13) Campbell SE, Laliberte L, Wolf-Jensen N, Grossman N, Hiris J, **Gordon LB**. A Medical and Research Database for Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation International Progeria Workshop, Boston, MA, Nov 2005.

14) Capell BC, Varga R, Erdos MR, Eriksson M, Madigan JP, Fiordalisi JJ, **Gordon LB**, Der CJ, Cox AD, Collins FS. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. The Progeria Research Foundation International Progeria Workshop, Boston, MA, Nov 2005.

15) Johnson EW, Gordon AS, Campbell S, Dokken C, **Gordon LB**. Clinical Testing for Lamin A (*LMNA*) Gene Mutations Associated with Hutchinson-Gilford Progeria Syndrome (HGPS): Review of the First Two Years of Testing. The Progeria Research Foundation International Progeria Workshop, Boston, MA, Nov 2005.

16) Lemire JM, **Gordon LB**, Sandy JD, Toole BP, Weiss AS. Hutchinson-Gilford Progeria Syndrome Alters Proteoglycan Production by Dermal Fibroblasts. The Progeria Research Foundation International Progeria Workshop, Boston, MA, Nov 2005.

17) Perry MB, Introne WJ, Merideth M, **Gordon LB**, Gahl WA, Gerber LH. Impairments and Functional Limitations in Hutchinson-Gilford Progeria. *Archives of Physical Medicine and Rehabilitation.* 87, E23, 2006.

18) Merideth MA, Introne WJ, **Gordon LB**, Smith ACM, Gahl WA. Clinical Presentation and Diagnosis of Patients with Hutchinson-Gilford Progeria Syndrome. ASHG Annual Meeting, New Orleans, LA, Oct 2006.

19) Introne WJ, Merideth M, **Gordon LB**, Perry M, Turner M, Clauss S, Sachdev V, Graf J, Smith ACM, Reynolds J, Yanovski J, Cannon R, Gahl WA. Hutchinson-Gilford Progeria Syndrome (HGPS): Consistency of phenotype in 15 children. ASHG Annual Meeting, New Orleans, LA, Oct 2006.

20) Capell BC, Erdos MR, Varga R, Olive M, Kolodgie F, Avallone H, San H, Qu X, **Gordon LB**, Virmani R, Nabel EG, Gahl WA, Collins FS. *In vitro* and *in vivo* effects of farnesyltransferase inhibitors for Hutchinson-Gilford progeria syndrome. Plenary Presentation, ASHG Annual Meeting, New Orleans, LA, Oct 2006.

21) Chen X, Erdos MR, Olive M, Capell BC, Cao K, Anderson SM, Kirby MR, Nabel EG, Collins FS, **Gordon LB**. *In vitro* investigation of the mechanism of vascular smooth muscle loss in Hutchinson-Gilford progeria syndrome. National Human Genome Research Institute Annual Scientific Retreat, Bethesda, MD, Nov 2006.

22) Cox AD, Madigan JP, Fiordalisi JJ, Der CJ, Berzat AC, Philips MR, Bivona T, Ahearn I, Quatela S, Capell BC, Erdos MR, **Gordon LB**, Varga R, Collins FS. Farnesylated proteins: how do they get to where they need to go, and how does location regulate their ability to control proliferation, death, transformation and aging? *The FASEB Journal.* 20, A852, 2006.

23) Zalewski C, Meredith M, Introne W, **Gordon LB**, Smith ACM, Kim J, Gahl W, Brewer C. Auditory Phenotype of Hutchinson-Gilford Progeria Syndrome. American Academy of Audiology Annual Conference, Denver, CO, Apr 2007.

24) Merideth MA, Introne WJ, **Gordon LB**, Perry MB, Clauss SB, Sachdev V, Zalewski CK, Brewer CC, Kim J, Graf J, Smith ACM, Gerber LH, Yanovski JA, Domingo DL, Hart TC, Collins FS, Nabel EG, Cannon RO, Gahl WA. Hutchinson-Gilford Progeria Syndrome (HGPS): Comprehensive characterization of 15 children. ASHG Annual Meeting, San Diego, CA, Oct 2007.

25) Harten IA, Johnson P, Braun K, Perigo S, Varga R, Erdos M, Kolodgie F, Olive M, San H, Qu X, Virmani R, Eriksson M, **Gordon LB**, Nabel EG, Collins FS, Wight TN. The Effect of Lamin AΔ50 Expression on Vascular Extracellular Matrix. The Progeria Research Foundation Workshop on Progeria, Boston, MA, Nov 2007.

26) Linnemann MR, Harten I, **Gordon LB**, Lemire J. Introduction of the mutation causing Hutchinson-Gilford Progeria into human coronary artery smooth muscle cells: a microarray study. The Progeria Research Foundation Workshop on Progeria, Boston, MA, Nov 2007.

27) Olive M, **Gordon LB**, Erdos M, Capell B, Harten I, Wight T, Collins F, Djabali K, Nabel E. Clinical and Molecular analysis of atherosclerosis in Progeria. The Progeria Research Foundation Workshop on Progeria, Boston, MA, Nov 2007.

28) Regen AC, Sonis A, Kieran M, Kleinman M, **Gordon LB**. Dental Manifestations Associated with Progeria Syndrome. The Progeria Research Foundation Workshop on Progeria, Boston, MA, Nov 2007.

29) McKarten K, **Gordon LB**. Progeria – Radiographic Review and Clinical Update. The Society for Pediatric Radiology, Annual Meeting, Carlsbad, CA, Apr 2009.

30) Campbell S, Fast L, Wolf-Jensen N, Grossman N, **Gordon LB**. The Progeria Research Foundation Programs: Stepping Stones to Treatment and Cure. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

31) Harten I, Olive M, Johnson P, Braun K, Chan C, Oshima J, Mitchell R, Virmani R, Erdos M, Collins F, Nabel E, **Gordon LB**, Wight T. The Effect of Progerin on Vascular Extracellular Matrix in Hutchinson Gilford Progeria Syndrome. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

32) Olive M, Harten I, Mitchell R, Beers J, Djabali K, Virmani R, Collins F, Wight T, Nabel E, **Gordon LB**. Cardiovascular Pathology in Hutchinson-Gilford Progeria; Correlates with the Vascular Pathology of Aging. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

33) Regen AC, Sonis AL, Kieran M, Kleinman M, **Gordon LB**. Dental Manifestations Associated with Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

34) Snyder B, Nazarian A, Gordon C, Kieran M, **Gordon LB**, Kleinman M, Miller D, Neuberg D, Giobbie-Hurder A. Effects of Progeria on the Structural Properties of the Appendicular Skeleton. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

35) Guardiani E, Zalewski C, Brewer C, Merideth M, Introne W, **Gordon LB**, Gahl W, Kim HJ. Audiological and otologic manifestations of Hutchinson-Gilford Progeria Syndrome. *Laryngoscope*. 120, S7, Oct 2010.

36) Ploski C, Riley S, **Gordon LB**, Kleinman M, Kieran M. Hip Range of Motion & Gross Motor Function & Their Relationship to Age in Children With Hutchinson-Gilford Progeria Syndrome (HGPS). American Physical Therapy Association Combined Sections Meeting, Poster 3066, San Diego, CA, Jan 2013.

37) Brazier J, Campbell S, Fast L, **Gordon LB**. PRF By the Numbers: A Data Sharing Tool. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

38) Correia A, Kieran M, **Gordon LB**. Outcome in Children with Hutchinson-Gilford Progeria Syndrome; An Occupational Therapy Perspective. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

39) Fast L, Campbell S, Brazier J, **Gordon LB**. The Progeria Research Foundation Cell and Tissue Bank and PRF Diagnostics Program. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

40) McSweeny KM, **Gordon LB**, Xu J, Ozel AB, Ping W, Arlt MF, Rajendran S, Li JZ, Glover TW. Searching for Mutations in Atypical Progeria. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

41) Rivera-Torres J, Llach A, Guzmán G, Herraiz A, González C, Jesús L, Borreguero J, Caballero R, Osorio FG, López-Otín C, Cabello N, Vallmitjana A, Benítez R, **Gordon LB**, Pérez-Pomares JM, Tamargo J, Delpón E, Hove-Madsen L, Andrés V. Pre-lamin A Accumulation Causes Arrhythmogenic Cardiomyopathy Linked to Defective Sarcoplasmic Reticulum Calcium Handling in Progeroid Zmpste24-null Mice. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

42) Nazarian A, Calderon N, Masoudi A, Gordon C, Kieran M, **Gordon LB**, Kleinman M, Miller D, Neuberg D, Giobbie-Hurder A, Snyder B. Effects of Progeria on the Structural Properties of the Appendicular Skeleton: Differences from "Normal" and After Treatment. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

43) Quinn N, Massaro J, Gordon C, **Gordon LB**, Kleinman M, Kieran M, Huh S. Energy Intake, Energy Expenditure and Body Composition in Children with HGPS. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

44) Rork J, Huang J, **Gordon LB**, Kleinman M, Kieran M, Liang M. Initial Cutaneous Manifestations of Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

45) Osman H, Fligor B, **Gordon LB**, Kleinman M, Kieran M. Increased Sensorineural Hearing Sensitivity in Children with Progeria During Lonafarnib Treatment. American Auditory Society Scientific and Technology Meeting, Scottsdale, AZ, Mar 2014.

46) Prakash A, **Gordon LB**, Kleinman M, D'Agostino Sr R, Massaro J, Kieran MW, Smoot L, and the Progeria Clinical Trials Collaborative. Diastolic Left Ventricular Dysfunction is a Common and Early

Cardiac Abnormality in Hutchinson-Gilford Progeria Syndrome. American Heart Association Scientific Sessions 2015, Orlando, FL, Nov 2015.

47) Prakash, A, **Gordon LB**, Kleinman, ME, D'Agostino, R, Massaro, J, Kieran, M, Gerhard-Herman, M, Smoot, L. Diastolic dysfunction is an early cardiac abnormality in progeria syndrome. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

48) Brazier JF, Campbell SE, Norris WE, **Gordon LB**. PRF By the Numbers Poster: A Data Sharing Tool. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

49) Brazier JF, Campbell SE, Norris WE, Glover TW, Arlt M, Bar D, Collins FS, Larrieu, D, **Gordon LB**. Somatic Mosaicism With Two Populations of Progerin-producing Mutations. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

50) Campbell SE, Fast, L, Massaro, JM, Moses MA, **Gordon LB**. Multiplex Screen of Plasma Biomarkers in Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

51) Norris WE, Brazier JF, Campbell SE, **Gordon LB**. The Progeria Research Foundation Cell and Tissue Bank Diagnostic Program. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

52) Bassir SH, Kokaras A, Paster BJ, Sonis A, **Gordon LB,** Kleinman ME, Kieran MW. Subgingival Microbial Profile of Individuals with Hutchinson-Gilford Progeria Syndrome: Comparison with Periodontal Health and Periodontal Disease Using Human Oral Microbe Identification Microarray. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

53) Mukundan S, Silvera M, Ullrich N, Kleinman ME, Kieran MW, Grant E, Chansakul T, Sarma A, **Gordon LB**. The Alphabet "Soup" of Brain Magnetic Resonance Imaging for Progeria. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

54) Fadel N, Brazier J, Campbell S, Kleinman ME, Kieran M, **Gordon LB**. Schema and Overview of Progeria Clinical Trials. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

55) Glover, TW, **Gordon LB**, Li, J, Kubisch, C, Campbell, S, Lessel, D, McSweeney, KM, Arlt, MF, Ozel AB, Song, Q, Kruger, A, Saadi. A. Identifying causative mutations in atypical progeria by exome Sequencing. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

56) Goodson R, Hamren S, Norris W, **Gordon LB.** Development of an Ultrasensitive Immunoassay for the Quantification of Progerin in Matrix. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

57) Greer M, Kleinman ME, **Gordon LB**, Gordon C. Menarche in Progeria. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

58) Ploski C, Correia A, Croteau J, Coucci S, **Gordon LB**, Kleinman ME, Kieran MW, Massaro J. Gross and Fine Motor Findings in a Small Cohort of Children with Classical Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

59) Ploski C, Coucci S, **Gordon LB**, Kleinman ME, Kieran MW, Massaro J. Relationship of Selected Lower Extremity (LE) Range of Motion (ROM) Impairments to Physical Performance and Age in Hutchinson-Guilford Progeria Syndrome. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

60) Shappell, H, Massaro, J, D'Agostino Sr., RB, Campbell, SE, Brazier, J, Kleinman, ME, Kieran, MW, **Gordon LB**, and Progeria Trials Collaborative. Update on Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation Scientific Workshop "Across the Table: Around the Globe," Cambridge, MA, May 2016.

61) Lunze FI, Biering-Sørenson T, Hedge SM, Colan SD, Smoot LB, **Gordon LB**, Kleinman ME, Kieran MW and Prakash A. Myocardial Deformation Analysis Reveals Early Cardiac Abnormalities in Patients with Hutchinson-Gilford Progeria Syndrome. American Heart Association Scientific Sessions, New Orleans, LA, Nov 2016.

62) Croteau J, Ploski C, Coucci S, Massaro JM, **Gordon LB**, Kleinman ME, Kieran MW, Correia A. Relationship Between Physical Impairments and Functional Performance in Children With Hutchinson-Gilford Progeria Syndrome. American Occupational Therapy Association Annual Conference & Centennial Celebration. Philadelphia, PA, Mar 30-Apr 2 2017.

63) Campbell SE, Brazier JF, Norris WE, **Gordon LB**. PRF By The Numbers and The Progeria Research Foundation Programs. The Progeria Research Foundation 9th International Scientific Workshop on Progeria "Basic and Clinical Science - Working Together Toward the Cure," Cambridge, MA, Sep 2018.

64) Croteau J, Berry E, Coucci S, Massaro J, Guary E, **Gordon LB**, Kleinman M, Correia, A, Ploski C. Physical Impairments and Challenges with Upper and Lower Body Dressing in Children With Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation 9th International Scientific Workshop on Progeria and Lower Body Dressing in Children With Hutchinson-Gilford Progeria Syndrome., Sep 2018.

65) Hamren S, Goodson R, **Gordon LB**, Norris W. The Power of Single Molecule Counting: The Future of Immunoassays. The Progeria Research Foundation 9th International Scientific Workshop on Progeria "Basic and Clinical Science - Working Together Toward the Cure," Cambridge, MA, Sep 2018.

66) Gordon CM, Cleveland RH, Baltrusaitis K, Massaro J, D'Agostino RB, Liang MG, Snyder B, Walters M, Li X, Braddock DT, Kleinman ME, Kieran MW, **Gordon LB.** Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome. The Progeria Research Foundation 9th International Scientific Workshop on Progeria "Basic and Clinical Science - Working Together Toward the Cure," Cambridge, MA, Sep 2018.

67) Norris W, Brazier J, Campbell S, **Gordon LB.** The Progeria Research Foundation Cell and Tissue Bank Diagnostic Program. The Progeria Research Foundation 9th International Scientific Workshop on Progeria "Basic and Clinical Science - Working Together Toward the Cure," Cambridge, MA, Sep 2018.

68) Koblan LW. Tavarez U, Levy J, Cabral W, Wilson C, G Yantenew, Mao X, Newby G, Doherty S, Davidson L, Lin C, **Gordon LB**, Cao K, Erdos M, Brown J, Collins F, Liu D. "Adenine base editing in Hutchinson-Gilford progeria syndrome," Keystone, CO Feb 2021.

69) Norris W, Collins F, Erdos M, Andres V, Misteli T, Puttaraju M, Foisner R, Cao K, Humphrey J, Brown T, Rigo F, Bennet F, **Gordon LB**. "Plasma Progerin in Animal Models of Hutchinson-Gilford Progeria Syndrome", Nov 2022.

70) Norris W, Tuminelli K, **Gordon LB**. "The Progeria Research Foundation Cell and Tissue Bank and Diagnostic Programs". Nov, 2022.

71) Tuminelli K, Maestranzi J , Norris W, Gordon L. "Patient Survey: COVID-19 Infection and Vaccination in Children and Young Adults with Progeria," Cambridge, MA, Nov 2022.

72) Kreienkamp R, Pendleton A, Schiferl D, **Gordon LB**, Gordon CM. " Abnormal Cortical Bone Structure and Strength in Hutchinson-Gilford Progeria Syndrome", Cambridge, MA Nov, 2022

73) Maestranzi J, Tuminelli K, Norris W, Sollecito C, **Gordon LB**. "PRF by the Numbers: The Progeria Research Foundation Programs, Cambridge, MA Nov, 2022.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA (Online):

1) Brown WT, **Gordon LB**, Collins FS. 2003. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2003.

2) Brown WT, **Gordon LB**, Collins FS. 2006. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2006.

3) **Gordon LB**, Brown WT, Collins FS. 2010. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2010.

4) **Gordon LB**. PRF by the Numbers at www.progeriaresearch.org/prf-by-the-numbers.html (The Progeria Research Foundation, 2013).

5) **Gordon LB**, Brown WT, Collins FS. 2015 Jan 8. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1121/.

6) **Gordon LB.** Hutchinson-Gilford Progeria in RareShare at http://www.raregenomics.org**;** Hanover (MD); 2016.

7) Acceptance into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program (BQP); Sept 5, 2018

8) **Gordon LB**, Brown WT, Collins FS. Hutchinson-Gilford Progeria Syndrome. 2003 Dec 12 [Updated 2019 Jan 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1121.

INVITED PRESENTATIONS:

REGIONAL:

1) **Gordon LB**. Aging and Progeria: Is there a common link through Lamin A? Genzyme Corporation, , Jul 2003.

2) **Gordon LB**, Introne W, Merideth M, Smith A, Graf J, Reynolds J, Yanovski J, Perry M, Gerber L, Brewer C, Kim H, Zalewski C, Gahl W. Hutchinson-Gilford Progeria Syndrome Objective Clinical Assessment Strategies: How will we know if treatments are improving disease? The Progeria Research Foundation International Progeria Workshop, Boston, MA, Nov 2005.

3) **Gordon LB**. Hutchinson Gilford Progeria Syndrome: Pathway to a Clinical Trial. Steering Committee Meeting, Department of Pediatric Neuro-oncology, Dana Farber Cancer Institute, Boston, MA, Feb 2007.

4) **Gordon LB**, Kleinman M. Treating Progeria with FTI. General Clinical Research Center, Staff In-service, Children's Hospital Boston, Boston, MA, Apr 2007.

5) **Gordon LB**, Berns SD. Progeria: From Obscurity to Treatment Trial. Grand Rounds, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI, Dec 2007.

6) **Gordon LB**, Berns SD. Lecture for Translational Research Group Independent Study Project, Progeria: From Obscurity to Treatment Trial. Alpert Medical School, Brown University, Providence, RI, Mar 2009.

7) **Gordon LB**. Progeria: from Obscurity to Treatment Trials and Beyond. Plenary Address, The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

8) **Gordon LB**, Kieran M, Kleinman M, Miller D. Understanding the Progeria Disease Phenotype – Essential Elements for Successful Trial Implementation. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

9) Gordon CM, Snyder B, **Gordon LB**, Huh S, Quinn N, Giobbie-Hurder A, Neuberg D, Kleinman M, Miller D, Kieran M. Growth, Bone Health and Endocrine Aspects of Progeria. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

10) Kieran M, **Gordon LB**, Kleinman M, Miller D. Clinical Trial Development in Children with Progeria. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

11) Ullrich NJ, Silvera M, Campbell S, Orbach D, **Gordon LB**. Neuroradiologic manifestations of cerebrovascular disease in Hutchinson-Gilford Progeria syndrome. The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.

12) **Gordon LB**, Berns S. Lecture: Topics in Translational Research and Technologies, "How Translational Research is Incorporated by Non-profit Organizations." Alpert Medical School, Brown University, Providence, RI, Apr 2010.

13) **Gordon LB**. Hutchinson-Gilford Progeria Syndrome: Clinical and Molecular Comparisons with Aging. Department of BioTherapeutics Research and Development, Pfizer Inc., Cambridge, MA, Aug 2010.

14) **Gordon LB**. Progeria: From Obscurity to Treatment Trials in a Decade. Running your first clinical study: A workshop on Harvard Catalyst Clinical Research Center resources, Harvard Medical School, Boston, MA, Dec 2010.

15) **Gordon LB**. Saving Children with Progeria: The Journey from Obscurity to Treatment and the Quest for a Cure. Orphan and Genetic Disease Summit, Pfizer Inc., Cambridge, MA, Feb 2011.

16) **Gordon LB**. The Progeria Journey - Finding Treatments and Cure for a Rare and Fatal Disease. Grand Rounds, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI, Jan 2012.

17) **Gordon LB**. Introduction to Essential Elements of Progeria. The Progeria Research Foundation Scientific Meeting: New Frontiers in Progeria Research, Boston, MA, Jan 2012.

18) **Gordon LB**. Breakout Session Leader, Rare Disease Day, Whitehead Institute, Cambridge, MA, Feb 2012.

19) **Gordon LB**. Panel Discussion on Progeria. Guest Speaker, Genetic Disorder Project Symposium, Harvard College, Boston, MA, May 2013.

20) **Gordon LB**. Lecture: Modern Genetics, Ethics and Policy, "Hutchinson-Gilford Progeria Syndrome." Alpert Medical School, Brown University, Providence, RI, Oct 2013.

21) **Gordon LB**. Saving Children with Progeria: The Journey from Obscurity to Treatment and the Quest for a Cure. Guest Speaker, Sarepta Therapeutics, Cambridge, MA, Aug 2013.

22) **Gordon LB**. Annual Justine Bonsignore Zompa, MD Memorial Lecture, "Hutchinson-Gilford Progeria Syndrome – From Obscurity to Treatment and Beyond." Women & Infants Hospital, Providence, RI, Oct 2014.

23) **Gordon LB**. The Clinical Core in Progeria. The Progeria Research Foundation Scientific Meeting: Across the Table: Around the Globe, Cambridge, MA, May 2016.

24) **Gordon LB**. Hutchinson-Gilford Progeria Syndrome: Progress Towards Treatments And Cure For An Ultra-Rare Fatal Pediatric Disease. Grand Rounds, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI, Sept 2016.

25) **Gordon LB**, Berns SD. Key Note Address on Progeria. National Council of University Research Administration (NCURA) Region 1 Spring Meeting, Newport, RI, May 2017.

26) **Gordon LB**. Progeria: The disease, the challenges and the history. Boston University Summer Institute of Biostatistics, In-service to Biostatistics students on Progeria, Boston University, Course BS401, Boston, MA, Jul 2018.

27) **Gordon LB**, Norris W, Massaro J, Goodson B, Hamre S, Moses M, Kieran MW, Kleinman ME. Progerin Biomarker Assay Development. The Progeria Research Foundation 9th International Scientific Workshop on Progeria "Basic and Clinical Science - Working Together Toward the Cure," Cambridge, MA, Sep 2018.

28) **Gordon LB**, Introduction to Progeria and Meeting Program Overview. The Progeria Research Foundation 9th International Scientific Workshop on Progeria "Basic and Clinical Science - Working Together Toward the Cure," Cambridge, MA, Sep 2018.

29) **Gordon LB**. Biochemical biomarker development in Progeria. The Progeria Research Foundation 9th International Scientific Workshop on Progeria "Basic and Clinical Science - Working Together Toward the Cure," Cambridge, MA, Sep 2018.

30) **Gordon LB**. Progeria. Radiology Department, X-Ray Technician In-service, Children's Hospital Boston, Boston, MA, Nov 2018.

31) **Gordon LB**. What is Progeria? Navitor Pharmaceuticals, Cambridge, MA Nov 2018.

32) **Gordon LB.** Lecture: Human Genetics and Genomics, "Hutchinson-Gilford Progeria Syndrome: Progress Towards Treatments And Cure For An Ultra-Rare Fatal Pediatric Disease." Brown University, Providence, RI, April 2019.

33) **Gordon LB**. Progeria: The disease, the challenges and the history. Boston University Summer Institute of Biostatistics, In-service to Biostatistics students on Progeria, Boston University, Course BS401, Boston, MA, Jul 2019.

34) **Gordon LB**. STAT News: Battle Scars: The Journey from Lab to Patient's Bedside. Presenter, Stories from the Lab, Boston May, 2022.

35) **Gordon L.B.** Progeria Aortic Stenosis Intervention Summit, Boston, MA May 2022.

36) **Gordon LB**. Progeria: The disease, the challenges and the history. Boston University Summer Institute of Biostatistics, In-service to Biostatistics students on Progeria, Boston University, Course BS401, Boston, MA, Jun 2022.

37) **Gordon LB**. The Lonafarnib Journey to Approval – Lessons for Future Treatments and the Cure. The Progeria Research Foundation 11th International Scientific Workshop on Race Progeria to the Cure," Cambridge, MA, Nov 2022.

38) **Gordon LB**. The Lonafarnib Journey to Approval – Lessons for Future Treatments and the Cure. The Progeria Research Foundation 11th International Scientific Workshop on Race Progeria to the Cure," Cambridge, MA, Nov 2022.

39) **Gordon LB**. Panel Presentation: Update on Progress in Development Program for SRP-2001 HGPS-specific RNA Therapy The Progeria Research Foundation 11th International Scientific Workshop on Race Progeria to the Cure," Cambridge, MA, Nov 2022.

40) **Gordon LB**. Panel Presentation: Base Editing to Rescue Progeria – Where Are We Now, and Where Do We Need to Go?. The Progeria Research Foundation 11th International Scientific Workshop on Race Progeria to the Cure," Cambridge, MA, Nov 2022.

NATIONAL:

1) **Gordon LB**. Hyaluronan in Hutchinson-Gilford Progeria Syndrome. National Institutes of Health/The Progeria Research Foundation Joint Workshop on Hutchinson Gilford Progeria Syndrome, Bethesda, MD, Nov 2001.

2) **Gordon LB**. The Progeria Research Foundation Cell Bank. National Institutes of Health/The Progeria Research Foundation Joint Workshop on Hutchinson Gilford Progeria Syndrome, Bethesda, MD, Nov 2001.

3) **Gordon LB**. A Medical and Research Database for Hutchinson-Gilford Progeria Syndrome. National Institutes of Health/The Progeria Research Foundation Joint Workshop on Hutchinson Gilford Progeria Syndrome, Bethesda, MD, Nov 2001.

4) **Gordon LB**. The Role of Hyaluronan in Hutchinson-Gilford Progeria Syndrome. Proteoglycans in the Clinic: Diagnosis and Therapy, Gordon Conference on Proteoglycans, Andover, NH, Jul 2002.

5) **Gordon LB**, Harten IA, Toole BP. Proteoglycans in the Clinic: Diagnosis and Therapy, Gordon Conference on Proteoglycans, Andover, NH, Jul 2002.

6) **Gordon LB**, Berns SD, Collins F. Panel Discussion: "Power of Collaboration". The Genetic Alliance Conference, Washington, DC, Aug 2003.

7) **Gordon LB**. Partnerships for Progress in Progeria Research. Opening Plenary Presentation, Gerontological Society of America, San Diego, CA, Nov 2003.

8) **Gordon LB**. Learn About Progeria: A Q&A with Dr. Leslie Gordon, MD, PhD, Medical Director of the Progeria Research Foundation (PRF). National Healthy Mothers Healthy Babies Coalition, Apr 2004. http://www.hmhb.org/virtual-library/interviews-with-experts/progeria/.

9) **Gordon LB**. The Progeria Research Foundation - A Global Resource for Working Towards a Cure. Department of Chemical Research, Schering-Plough Research Institute, Kenilworth, NJ, Nov 2004.

10) **Gordon LB**. The Progeria Research Foundation - A Global Resource for Working Towards a Cure. Johnson & Johnson Corp., New Brunswick, NJ, Nov 2004.

11) **Gordon LB**. Prospects for Therapy of HGPS and the Role of the Progeria Research Foundation in Supporting Research. Plenary Presentation, Gerontological Society of America, Washington, DC, Nov 2004.

12) **Gordon LB**. Natural History Study of Progeria. Nursing In-service, Clinical Center, National Institutes of Health, Bethesda, MD, Dec 2004.

13) **Gordon LB**. Perspectives on Progeria: The Power of Partnerships. Speech, American Society for Cell Biology Summer Meeting on Nuclear Architecture and Human Disease, Iowa State University, Ames, IA, Jul 2005.

14) **Gordon LB**. Hutchinson Gilford Progeria Syndrome: Pathways Towards Treatment. Rehabilitation Department Grand Rounds, Clinical Center, National Institutes of Health, Bethesda, MD, Dec 2005.

15) **Gordon LB**, Misteli T. Drug Discovery in Progeria: Potential New Strategies for Treating Heart Disease and Aging: High Through-Put Assays to Identify Small Molecules that Modulate mRNA Splicing. Schering-Plough Research Institute, Kenilworth, NJ, Sep 2008.

16) **Gordon LB**, Collins FC, Kieran M. Panel Discussion: Translating Progeria: a Bench-to-Bedside Story. 48th Annual Meeting of the American Society for Cell Biology, San Francisco, CA, Dec 2008.

17) **Gordon LB**. Advancing Rare Disease Research Through Networks and Collaboration; Clinical Research to Clinical Practice Translation Panel, NIH, Bethesda, MD, July, 2009

18) **Gordon LB**, Gordon A. Clues to Aging through Progeria Research. Fastercure - Partnering for Cures, New York, NY, Dec 2009.

19) **Gordon LB**. The Need for Data Collection to Accelerate Rare Disease Research. Genetic Alliance Registry and Repository Bootcamp, Bethesda, MD, Jan 2010.

20) **Gordon LB**. Essential Elements for Translational Research in Rare Diseases: Progeria as a Case Study and Panel Discussion. NIH Office of Rare Diseases: Advancing Rare Disease Research: The Intersection of Patient Registries, Biospecimen Repositories and Clinical Data, NIH, Bethesda, MD, Jan 2010.

21) **Gordon LB**. Patient Participation/Outreach Activities and Patient Advocacy Panel Discussion. NIH Office of Rare Diseases: Advancing Rare Disease Research: The Intersection of Patient Registries, Biospecimen Repositories and Clinical Data, NIH, Bethesda, MD, Jan 2010.

22) **Gordon LB**, Berns SD. Clues to Aging through Progeria Research. PhRMA Annual Meeting, Arlington, VA, Mar 2010.

23) **Gordon LB**. Hutchinson-Gilford Progeria Syndrome: Molecular and Clinical Comparison with Aging. Department of Genetics and Center for Genetics in Health and Disease, University of Michigan, Ann Arbor, MI, May 2010.

24) **Gordon LB**. Hutchinson-Gilford Progeria Syndrome: A New Avenue for Cardiovascular and Aging Research through Rare Disease Discoveries. Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, Dec 2010.

25) **Gordon LB**. Panel discussion: Therapy Development, Lessons Learned, Part II: Novel Strategies and Relationships. Genetic Disease of Children: Advancing Research and Care Conference, New York, NY, Mar 2011.

26) **Gordon LB**. Keynote Presenter, International Meeting on Genetic Syndromes of the Ras/MAPK Pathway: Finding Our Way Back to the Bedside, Chicago, IL, Jul 2011.

27) **Gordon LB**. Young Investigator Competition Judge, International Meeting on Genetic Syndromes of the Ras/MAPK Pathway: Finding Our Way Back to the Bedside, Chicago, IL, Jul 2011.

28) **Gordon LB**. Clinical Trial Panel Discussion Moderator, International Meeting on Genetic Syndromes of the Ras/MAPK Pathway: Finding Our Way Back to the Bedside, Chicago, IL, Jul 2011.

29) **Gordon LB**. Hutchinson-Gilford Progeria Syndrome: Translational Medicine from Gene Discovery to Treatment Trials. Plenary Speaker, 43rd Annual March of Dimes Clinical Genetics Conference: Genetics of Aging - From Progeroid Syndromes to Centenarians/ American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, Charlotte, NC, Mar 2012.

30) **Gordon LB**. Outcome Measures for Clinical Treatment Trials in HGPS - Is Longevity a Viable Option? The Progeria Research Foundation Scientific Workshop "Hand in Hand: Basic & Clinical Science Working Together Toward the Cure," Bethesda, MD, Apr 2013.

31) **Gordon, LB**. Theme: The Difference that Makes a Difference. TEDxCharlottesville, Charlottesville, VA, Nov 2013.

32) **Gordon LB**. The Possibility of Using AAV Based Antisense Oligo Expression for HGPS Treatment. Speaker, Clinical Center, National Institutes of Health, Bethesda, MD, Dec 2013.

33) **Gordon LB**. The Progeria Research Foundation as a Model for Developing Therapy. ACMG Annual Clinical Genetics and Genomics Meeting, Session entitled "Syndrome Specific Specialty Clinics and Networks: Enhancing Care and Research", University of Utah, Salt Lake City, UT, Mar 2015.

34) **Gordon LB**, Berns S. Keynote Presenter, PHACE Syndrome Family Conference: The Journey: From obscurity, to cause, treatments and the cure for children with Progeria, Atlanta, GA, Jun 2018.

35) **Gordon, LB**. Keynote Presenter, Celebratory Symposium for Robert D. Goldman: Words by Leslie Gordon and Lori Sames, Chicago, IL, Sep 2018.

36) **Gordon LB**, Berns S. Keynote Presenter, Patient-Centered Outcomes Research Institute (PCORI): Making a Difference: Using Patient-Centered Research Results in the Real World, Washington, DC, Sep 2019.

37) **Gordon LB. Presenter,** Presenter, Gordon Research Conference**.** Progeria - Strategies for Success in Moving from Benchside Discoveries to Patient Treatments, West Dover, VT, June 2020.

38) **Gordon LB.** Presenter, Chan Zuckerberg Science Initiative's Rare As One Network: Lightning talks: Nuts and Bolts - Building a collaborative research network, Berkeley, CA, July, 2020.

39) **Gordon LB.** Presenter, DeBakey CV Live: At the Cutting Edge of Cardiovascular Science: Insights Into Aging From Progeria, Houston, TX, November 9, 2020.

40) Gordon, LB. How an Ultra-Rare Disease Patient Organization Drove Research to a Treatment, RARECAST, The Global Genes Podcast, Episode #312, Aliso Viejo, CA, December 11, 2020. https://globalgenes.org/rare-cast/episode-312.

41) **Gordon LB**, Liu D. Progeria: Journey to the Cure, Beam University, Beam Therapeutics, Cambridge, MA, January 28 2021.

42) **Gordon LB.** Lonafarnib Development Program for the Treatment of Hutchinson-Gilford Progeria Syndrome, The Rare Diseases Team within the Office of New Drugs, CDER, FDA, March 2, 2021.

43) **Gordon LB**. Drivers of Progress in Translational Sciences, ACTS: Association for Clinical Translation Science, April 2, 2021.

44) Collins, FS. Liu, Basso B, **Gordon LB**, Molteni M. Does genetics + CRISPR = medicine?, STAT: Breakthrough Science Summit: Virtual Event, July, 2021.

45) **Gordon, LB**, And That Has Made All The Difference: Patient Family-driven Progress for Children with Progeria, GM1 Foundation International GM1 Virtual Community Conference, September 2021.

46) **Gordon L.B.** Presenter, Regulatory Fitness in Rare Disease Clinical Trials: U.S. Food and Drug Administration's Center for Drug Evaluation and Research, May 2022.

47) **Gordon L.B.** Presenter, Duke-FDA Meeting Invitation | Translational Science in Drug Development: Surrogate Endpoints, Biomarkers, and More, May 2022.

INTERNATIONAL:

1) **Gordon LB**. The Progeria Research Foundation: A Global Resource for Families, Physicians and Researchers towards Finding a Cure for Progeria. Europrogeria Meeting, Marseille, France, Sep 2004.

2) **Gordon LB**. Advances in HGPS research and the New FTI Clinical Trial. Meeting on Cell Senescence, Oriel College, Oxford, United Kingdom, Jul 2008.

3) **Gordon LB**. The Progeria Story - A Model for Translational Research. Speaker, Vascular Inflammation, Aging and Imaging Conference, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Apr 2012.

4) **Gordon LB**. Vascular Aging. Session Chair. Vascular Inflammation, Aging and Imaging Conference, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Apr 2012.

5) **Gordon LB**. Clinical Trial of a Farnesyltransferase Inhibitor in Children with Hutchinson-Gilford Progeria Syndrome. Italy Progeria Reunion, Montegrotto Terme, Italy, Sep 2012.

6) **Gordon LB**. Progeria: A paradigm for translational medicine. Symposium entitled "S1-03 Genetics of Longevity/Aging," 26th Joint Meeting of the German, Austrian and Swiss Societies of Human/Medical Genetics, Karl-Franzens-University, Graz, Austria, Apr 2015**.**

7) **Gordon LB**. Clinical trials in progeria patients: Nobel Mini-Symposium titled, "Premature aging: From basic research to clinical treatment in a decade," Karolinska Institutet, Stockholm, Sweden, May 2016.

8) **Gordon LB**. The Progeria Foundation and its global role: The Second Workshop of the Center for Complexity and Biosystems, University of Milan, Italy, Oct 2016.

9) **Gordon LB.** Program and progress towards treatments and the cure for children with Progeria**:** International Meeting on RECQ Helicases and Related Diseases 2018, Chiba University, Japan, Feb 2018.

10) **Gordon LB**. 9th UK Nuclear Envelope Disease and Chromatin Organisation Meeting and 3rd International Meeting on Laminopathies, Kings College London, Nov 2019.

11) **Gordon LB**. Progress, Lessons and the Future of Clinical Trials for Hutchinson-Gilford Porgeria Syndrome, 9th Nuclear Envelope Disease and Chromatin Organisation Meeting and 3rd International Meeting on Laminopathies, Kings College London, Sep 2019.

12) **Gordon LB**. Making a Difference for Children with Progeria: From Obscurity to Treatment and Beyond, CORD; The 9th China Rare Disease Summit, ChangDu, China, Sep 2020.

13) **Gordon LB.** Therapeutic approaches in Hutchinson-Gilford Progeria Syndrome, AELIP; Asociacion Internacional de Familiares y Afectados de Lipodistrofias, VIII International Lipodystrophies Symposium 2020 Working for Lipodystrophies, Barcelona, Spain, October, 2020.

14) **Gordon LB.** Progeria: from cell biology to FDA approval therapeutics, Biomed at TAU Research Hub Molecular Biology of Aging. Israel, March 8, 2021.

15) **Gordon, L.**B. Progeria: progress toward the cure, Zhejiang University International forum of Undiagnosed and Rare Disease, Virtual Presentation: China, on Sep 11, 2021.

16) **Gordon, LB.** Making a Difference for Children with Progeria: From Obscurity to Treatment and Beyond, XLVI National Congress of Human Genetics Virtually modality. Mexico, November, 2021.

17) **Gordon, LB** Making a Difference for Children with Progeria: From Obscurity to Treatment and Beyond University of the Philippines Manila, June 2022.

18) **Gordon, LB** Hutchinson-Gilford Progeria Syndrome: Programs Built and Lessons Learned In Our Journey Towards Treatments And**:** Argonautes University of Regensburg, Germany, August, 2022.

OTHER PRESENTATIONS/ SCIENTIFIC MEETING LEADERSHIP

My roles in meetings listed below were formation of a scientific leadership committee, scientific program design (plenary, oral and poster presentations), logistical design, coordination, session pre-meetings, meeting chair, session moderator, scientific presentations, grant submissions to fund meetings, and post-meeting activities as needed.

1) **Meeting Chair and Session Moderator:** National Institutes of Health/The Progeria Research Foundation Joint Workshop on Hutchinson Gilford Progeria Syndrome, Bethesda, MD, Nov 2001.
Open Registration; Registrant number – 46; Registrant Countries - 3

2) **Meeting Chair and Moderator:** The Progeria Research Foundation Genetics Consortium Meeting, Brown University, Providence, RI, Jul 2002.
Specialized meeting, invitation only

3) **Meeting Chair and Moderator:** The Progeria Research Foundation Genetics Consortium Meeting– "Post-gene Discovery", Bethesda, MD July 2003.
Specialized meeting, invitation only

4) **Meeting Chair and Session Moderator:** National Institutes of Health/The Progeria Research Foundation Joint Workshop on Hutchinson Gilford Progeria Syndrome, Bethesda, MD, Jul 2003.
Open Registration; Registrant number – 56; Registrant Countries - 5

5) **Meeting Chair and Moderator:** National Institutes of Health/The Progeria Research Foundation Joint Workshop: Stem Cell Transplantation in Hutchinson Gilford Progeria Syndrome, NHGRI, Bethesda, MD, Apr 2004.
Specialized meeting, invitation only

6) **Meeting Chair and Session Moderator**: The Progeria Research Foundation International Workshop on Progeria, Boston, MA, Nov 2005.
Open Registration; Registrant number – 90; Registrant Countries - 10

7) **Meeting Chair and Session Moderator:** The Progeria Research Foundation Workshop on Hutchinson-Gilford Progeria, Boston, MA, Nov 2007.
Open Registration; Registrant number – 100; Registrant Countries - 10

8) **Meeting Chair and Session Moderator:** The Progeria Research Foundation 10th Anniversary Workshop on Progeria "From Bench to Bedside in a Decade," Boston, MA, Apr 2010.
Open Registration; Registrant number – 140; Registrant Countries - 10

9) **Meeting Chair and Moderator:** The Progeria Research Foundation Scientific Meeting: New Frontiers in Progeria Research, Boston, MA, Jan 2012.
Specialized meeting, invitation only

10) **Meeting Chair and Session Moderator:** The Progeria Research Foundation Workshop on Progeria "Hand in Hand: Basic & Clinical Science Working Together Toward a Cure," Bethesda, MD, Apr 2013.
Open Registration; Registrant number – 180; Registrant Countries – 18

11) **Meeting Chair, Session Moderator and Presenter:** The Progeria Research Foundation Medical Research Committee Summit, Cambridge, MA, Dec 2015.

12) **Meeting Chair and Session Moderator:** The Progeria Research Foundation 8th International Scientific Workshop, "Across the Table, Around the Globe" Cambridge, MA, May 2-4, 2016.
Open Registration: Registrant number – 173; Registrant Countries 14

13) **Meeting Chair and Session Moderator:** The Progeria Research Foundation 9th International Scientific Workshop, "Basic Clinical Science Working Together Toward the Cure" Cambridge, MA, September 20-22, 2018.
Open Registration: Registrant number – 163; Registrant Countries – 14

14) **Meeting Chair and Moderator:** The Progeria Research Foundation's 10th International Scientific Workshop, "Researching Possibilities, ExTENding Lives" Webinar, November 2 and 3, 2020.
Open Registration: Registrant Number – 377; Registrant Countries – 30.

15) **Meeting Chair:** The Progeria Research Foundation 11th International Scientific Workshop, "Race Progeria to the Cure" Cambridge, MA, November, 2022.
Open Registration: Registrant number – 125; Registrant Countries – 14.

GRANTS:

PAST FUNDING:

1) Institutional Research Grant, **American Cancer Society**, ACS IN-45-34, Principal Investigator, 1992-1994, **$3,000**.

2) The Pathophysiology of Atherosclerosis in Hutchinson-Gilford Progeria Syndrome, Scientist Development Grant**, American Heart Association,** 0030217N, Principal Investigator, 2000-2003, **$240,000**.

3) The Joint Workshop on Hutchinson-Gilford Progeria Syndrome, Conference Grant, **The Ellison Medical Foundation**, AG CW-0045-01, Principal Investigator, Nov 2001, **$8,953.50**.

4) The Role of Hyaluronic Acid in Hutchinson-Gilford Progeria Syndrome, **Progeria Research Foundation,** PRF-2000-002, Principal Investigator, 2000-2004, **$104,000**.

5) The Pathophysiology of Atherosclerosis in Hutchinson-Gilford Progeria Syndrome, **Natalie V. Zucker Research Center for Women Scholars**, Principal Investigator. May 2003, **$4,736**.

6) Joint Workshop on Hutchinson-Gilford Progeria Syndrome, **National Heart Lung and Blood Institute, National Institutes of Health**, Principal Investigator, Jul 2003, **$10,000**.
.

7) Creating a Medical and Research Database for HGPS, Exploratory/Development Grant, **National Institute on Aging**, NIH 1R21AG021902-01, Principal Investigator, Jun 2003, **$200,000**.

8) The role of Lamin A in Hutchinson-Gilford Progeria Syndrome**, March of Dimes, Basil O'Connor Award,** M210001 - PV3895, Principal Investigator, Jan 2004-Jan 2006, **$100,000**.

9) The 2005 International Workshop on Progeria, **National Heart Lung and Blood Institute**. National Institutes of Health, 1R13HL085078-01, Principal Investigator, Nov

2005-Feb 2006, **$25,000**.

10) The Progeria Research Foundation International Workshop on Progeria**, The Ellison Medical Foundation,** Conference Grant, AG CW 0220-05, Principal Investigator, Nov 2005, **$10,000**.

11) The Progeria Research Foundation International Workshop on Progeria**, Max and Victoria Dreyfus Foundation,** Principal Investigator, Nov 2005, **$5,000**.

12) Clinical Investigations into Hutchinson-Gilford Progeria Syndrome **National Human Genome Research Institute, Natural History Study,** Associate Investigator, Oct 2004-Oct 2007.

13) Testing Treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) with Farnesyltransferase Inhibitors, **Office of Rare Diseases, National Institutes of Health,** Bench to Bedside Award, Principal Investigator, Jun 2005-Jun 2007, **$200,000**.

14) An open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) SCH66336 (Lonafarnib) for patients with Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid laminopathies**, Progeria Research Foundation,** Clinical Trial Grant PRFCLIN2007-01, Co-principal Investigator, Jan 2007-Oct 2009, **$1,077,000**.

15) The 2007 Progeria Research Foundation Workshop on Hutchinson-Gilford Progeria, National Institutes of Health Conference, **National Heart Lung and Blood Institute and Office of Rare Diseases**, Grant 1 R13 HL091695-01, Co-principal Investigator, Sep 2007-Aug 2008, **$30,000.**

16) The 2007 Progeria Research Foundation Workshop on Hutchinson-Gilford Progeria **The Ellison Medical Foundation,** Conference Grant, AG-CW-0258-07, Co-principal Investigator, Nov 2007, **$10,000**.

17) A phase I pilot study of zoledronic acid, pravastatin, and Lonafarnib (SCH66336) for patients with Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies, **Progeria Research Foundation Clinical Trial Grant**, PRFCLIN2009-02, Co-principal Investigator, Feb 2009-May 2009, **$44,787**.

18) Phase II Trial of Lonafarnib, Pravastatin and Zoledronic Acid in Progeria, **NHLBI Division of Cardiovascular Sciences**, Heart Development and Structural Diseases Branch FY 2009 Recovery Act, 1RC2HL101631-0. Co-principal Investigator, Sep 2009-Sep 2013**, $3,300,000**.

19) The 2010 Progeria Research Foundation Workshop on Progeria – From Bench to Bedside in a Decade, **The Ellison Medical Foundation,** Conference Grant, AG-CW-0312-10, Principal Investigator, Apr 2010, **$10,000**.

20) The 2010 Progeria Research Foundation Workshop on Progeria - From Bench to Bedside in a Decade, **Max and Victoria Dreyfus Foundation** Principal Investigator, Apr 2010, **$3,000**.

21) The 2010 Progeria Research Foundation Workshop on Progeria - From Bench to Bedside in a Decade, **American Federation for Aging Research,** Principal Investigator, Apr 2010, **$1,500**.

22) The 2010 Progeria Research Foundation Workshop on Progeria – From Bench to Bedside in a Decade, **National Heart Lung and Blood Institute and Office of Rare Disease Research**, National Institutes of Health Conference Grant, 1 R13 HL103229-01, Principal Investigator, Apr 2010, $**20,000**.

23) PRF 11th Anniversary Workshop on Progeria – Hand in Hand: Basic & Clinical Science Working Together Toward the Cure **National Institute on Aging**, 1R13AG046918-01, Principal Investigator, Apr 2013, **$13,500**.

24) The 2016 Progeria Research Foundation Scientific Workshop on Progeria – Across the Table: Around the Globe, **American Federation for Aging Research**, Principal Investigator, May 2016, **$2,500**.

25) The 2016 Progeria Research Foundation Scientific Workshop on Progeria – Across the Table: Around the Globe, **Carly Cares**, Principal Investigator, May 2016, **$10,000**.

26) The 2016 Progeria Research Foundation Scientific Workshop on Progeria – Across the Table: Around the Globe, **The Max and Victoria Dreyfus Foundation, Inc**., Principal Investigator, May 2016, **$5,000**.

27) The 2016 Progeria Research Foundation Scientific Workshop on Progeria – Across the Table: Around the Globe, **DSF Charitable Foundation**, Principal Investigator, May 2016, **$20,000**.

28) The 2016 Progeria Research Foundation Scientific Workshop on Progeria – Across the Table: Around the Globe, **Hologic**, Principal Investigator, May 2016, **$20,000**.

29) The 2016 Progeria Research Foundation Scientific Workshop on Progeria – Across the Table: Around the Globe, **National Institute on Aging**, NIH 1R13AG054149-01, Principal Investigator, May 2016, **$35,000**.

30) Discovering Novel Non-Invasive Biomarkers for Hutchinson-Gilford Progeria Syndrome, **Progeria Research Foundation,** PRF-2014-54, Co-principal Investigator, 2015–2017, **$150,000**

31) The 2018 The Progeria Research Foundation 9th International Scientific Workshop on Progeria – Basic And Clinical Science Working Together Toward The Cure, **National Institute on Aging**, NIH 1R13-PA-13-347, Principal Investigator, September 2018, **$47,500**.

32) The 2018 The Progeria Research Foundation 9th International Scientific Workshop on Progeria – Basic And Clinical Science Working Together Toward The Cure, **DSF Charitable Foundation**, Principal Investigator, September 2018, **$25,000**.

33) The 2018 The Progeria Research Foundation 9th International Scientific Workshop on Progeria – Basic And Clinical Science Working Together Toward The Cure, **Carley Cares**, Principal Investigator, September 2018, **$1,000**.

34) The 2018 The Progeria Research Foundation 9th International Scientific Workshop on Progeria – Basic And Clinical Science Working Together Toward The Cure, **Glenn Foundation for Medical Research**, Principal Investigator, September 2018, **$3,000**.

35) The 2018 The Progeria Research Foundation 9th International Scientific Workshop on Progeria – Basic And Clinical Science Working Together Toward The Cure, **Jack & Pauline Freeman Foundation**, Principal Investigator, September 2018, **$1,000**.

36) Phase I/II Trial of Everolimus in Combination with Lonafarnib in Progeria, **Boston Children's Hospital, Mooney Family Initiative for Translational and Clinical Studies in Rare Diseases,** Project 95515, Co-principal Investigator, 2016–2018.
$156,000.

37) A Pilot Study for Natural History of Cardiovascular and Dental Disease in Hutchinson Gilford Progeria Syndrome (HGPS) **Novartis** Grant# IRB-A00006554-2, Co-principal Investigator, 2013-2019, **$50,995.80**.

CURRENT FUNDING:

1) The Pathophysiology of Atherosclerosis in Hutchinson-Gilford Progeria Syndrome, **Progeria Research Foundation,** PRF-1999-001, Principal Investigator, 1999-Present, **$76,390**.

2) The Progeria Research Foundation International Progeria Registry, **Progeria Research Foundation Project**, PRF-1999-IR, Principal Investigator, 1999.

3) The Progeria Research Foundation Diagnostic Testing Program, **Progeria Research Foundation Project**, PRF-2003-DT, Principal Investigator, 2003-present.

4) The Progeria Research Foundation Cell and Tissue Bank, **Progeria Research Foundation Project,** PRF-2002-CB, Principal Investigator, 1999-Present.

5) Creating a Medical and Research Database for Hutchinson-Gilford Progeria Syndrome, **Progeria Research Foundation Project**, PRF-2002-MRD, Principal Investigator, 1999-Present.

6) An open label phase II trial of zoledronic acid, pravastatin, and lonafarnib (SCH66336) for patients with Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies, **Progeria Research Foundation,** Clinical Trial Grant #PRFCLIN2009-03, Co-principal Investigator, May 2009-Present, $**4,100,000**.

7) Natural History Studies of Progeria, **The Progeria Research Foundation**, PRF-2012-NH, **Principal Investigator,** 2012 – Present

8) Progerin Detection as a Pivotal Biomarker for Hutchinson-Gilford Progeria Syndrome, Heart Disease and Aging, **The Progeria Research Foundation** and **Singulex** SMC Technology Innovation Award, Principal Investigator, 2015-Present, **$150,000**.

9) Phase I/II Trial of Everolimus in Combination with Lonafarnib in Progeria, **The Progeria Research Foundation,** PRFCLIN2016-04, Co-principal Investigator, 2016–present. $3,800,000.

10) Progerin as a Biomarker for Hutchinson-Gilford Progeria Syndrome, **Food and Drug Administration**, Grant Number: 1U01FD006886-01, Principal Investigator, September, 2019 - August, 2020. **$243,185.**

11) The Progeria Research Foundation's 10th International Scientific Workshop, Researching Possibilities: Extending Lives**,** National Institute on Aging, NIH 1R13-PA-18-648, Principal Investigator, May 2023, **$50,000.**

12) Identification of biomarkers to monitor the progression of Hutchinson Gilford progeria syndrome ("ProgerOmics"), **European Joint Programme Rare Diseases Joint Transnational Call 2022**, Reference: EJPRD22-049), Collaborator, 2023-2025.

PATENTS ISSUED:

1) Title: *LMNA* GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS
U.S. Patent No. 7,297,492
Authors: Eriksson, Maria, H., Collins, Francis, S., **Gordon, Leslie, B**. Brown, Ted, W.
Date of Issue: November 20, 2007

2) Title: FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS
U.S. Patent No. 7,838,531
Authors: **Gordon, Leslie, B**. Collins, Francis, S. Glover, Thomas Glynn, Michael, W. Capell, Brian, C. Cox, Adrienne, D. Der, Channing, J.**;**
Date of Issue: November 23, 2010

3) Title: *LMNA* GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS
U.S. Patent No. 8,034,557
Authors: Eriksson, Maria, H., Collins, Francis, S., **Gordon, Leslie, B**. Brown, Ted, W.
Date of Issue: October 11, 2011

4) Title: FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS
U.S. Patent No. 8,257,915
Authors: **Gordon, Leslie, B**. Collins, Francis, S. Glover, Thomas Glynn, Michael, W. Capell, Brian, C. Cox, Adrienne, D. Der, Channing, J.**;**
Date of Issue: September 4, 2012

5) Title: *LMNA* GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS
U.S. Patent No. 8,535,884
Authors: Eriksson, Maria, H., Collins, Francis, S., **Gordon, Leslie, B**. Brown, Ted, W.
Date of Issue: September 17, 2013

6) Title: FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS
U.S. Patent No. 8,691,501
Authors: **Gordon, Leslie, B**. Collins, Francis, S. Glover, Thomas Glynn, Michael, W. Capell, Brian, C. Cox, Adrienne, D. Der, Channing, J.**;**
Date of Issue: April 8, 2014

7) Title: FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS
U.S. Patent No. 8,828,356
Authors: **Gordon, Leslie, B**. Collins, Francis, S. Glover, Thomas Glynn, Michael, W. Capell, Brian, C. Cox, Adrienne, D. Der, Channing, J.**;**
Date of Issue: September 9, 2014.

8) Title: LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS
U.S. Patent No. 9,115,400
Authors: Eriksson, Maria, H., Collins, Francis, S., **Gordon, Leslie, B**. Brown, Ted, W.
Date of Issue: August 25, 2015

9) Title: "COMBINATION THERAPIES FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING, AND ATHEROSCLEROSIS"
U.S. Patent No. 9,381,203
Authors: **Gordon, Leslie, B**. Kieran, Mark W. Kleinman, Monica E.
Date of Issue: July 5, 2016

10) Title: "COMBINATION THERAPIES FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING, AND ATHEROSCLEROSIS"
U.S. Patent No. 10,098,871
Authors: **Gordon, Leslie, B**. Kieran, Mark W. Kleinman, Monica E.
Date of Issue: October 18, 2018

111. Title: "METHODS FOR TREATING PROGERIOD LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA"
U.S. Patent No. 9,326,992
Date of Issue: March 3, 2016
U.S. Patent No. 9,388,468
Date of Issue: December 5, 2017
U.S. Patent No. 10,398,721
Date of Issue: September 3, 2019
DE Patent No. 602012044285.9
Date of Issue: March 21, 2018
FR, GB, IE, NL Patent No. 278848 (from EP Patent)
Date of Issue: March 21, 2018
Authors: **Gordon, Leslie, B.** Kole, Ryszard, Collins, Francis, S., Erdos, Michael, M. Cao, Kan.

JP Patent No. 6132849
Date of Issue: May 31, 2017
JP Patent No. 6596032
Date of Issue: October 23, 2019

PATENTS PENDING:

1) Title: "OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA"
U.S. Patent Application No. 17/024,100
Date of Filing April 28, 2017WO Patent Application No. PCT/US2017/030174
Date of Filing: April 28, 2017
AU Patent Application No. 2017258642
Date of Filing: April 28, 2017
BR Patent Application No. BR1120180722790
Date of Filing: April 28, 2017
CA Patent Application No. 3022303
Date of Filing: April 28, 2017
CN Patent Application No. 201780040785.7
Date of Filing: April 28, 2017
CO Patent Application No. 2017258642
Date of Filing: April 28, 2017
EA Patent Application No. NC2018/0012873
Date of Filing: April 28, 2017
EP Patent Application No. 17735676.3
Date of Filing: April 28, 2017
IN Patent Application No. 201847043433
Date of Filing: April 28, 2017
JP Patent Application No. 2019-508165
Date of Filing: April 28, 2017
KR Patent Application No. 10-2018-7034615
Date of Filing: April 28, 2017
MX Patent Application No. MX/A2018/013157
Date of Filing: April 28, 2017
Authors: **Gordon, Leslie, B.** Kole, Ryszard, Collins, Francis, S., Erdos, Michael, M. Cao, Kan.

2) Title: "COMBINATION THERAPIES FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING, AND ATHEROSCLEROSIS"
U.S. Patent Application No. 16/916,145, published as US 2020/0330443
Authors: **Gordon, Leslie, B**. Kieran, Mark W. Kleinman, Monica E.
Date of Filing: October 15, 2018

UNIVERSITY TEACHING, ADVISING and Mentoring ROLES:

LECTURES:

1) **Gordon LB.** Brown University Undergraduate Student Mentoring: Student assistant, Progeria Programs based at the Center for Gerontology and Healthcare Research, one student per semester, plus summer sessions, September, 2006-present.

2) **Gordon LB**. Guest Lecturer, Disease and Intervention. The Adolescent Leadership Council of Hasbro Children's Hospital, Brown University, Providence, RI, Apr 2007.

3) **Gordon LB**, Berns SD. Lecture for Translational Research Group Independent Study Project, Progeria: From Obscurity to Treatment Trial. Alpert Medical School, Brown University, Providence, RI, Feb 2008.

4) **Gordon LB**, Berns SD. Lecture for Translational Research Group Independent Study Project, Progeria: From Obscurity to Treatment Trial. Alpert Medical School, Brown University, Providence, RI, Mar 2009.

5) **Gordon LB**. Guest lecturer, How Translational Research is Incorporated by Non-profit Organizations. Topics in Translational Research and Technologies, Brown University, Providence, RI, Apr 2010.

BROWN UNIVERSITY UNDERGRADUATE STUDENT MENTORSHIP:

Undergraduate students work within the NIH and PRF funded Progeria programs: Overall, their experiences include a general educational experience with research on a rare disease population. Detailed responsibilities include copying and organizing of confidential medical records and digital film studies, Excel spreadsheet maintenance, data entry, document editing, obtaining manuscripts, and filing. Additional responsibilities may include preparation of kits/mailers and documents for the collection of biological samples. All students complete training in human subject's research and become well-versed in the proper procedures to protect confidential patient medical information and research data.

1) **Gordon LB.** Brown University Undergraduate Student Mentor to Annie Wang, 2/16/06-11/15/07, Alpert Medical School, Major/concentration: Program in Liberal Medical Education, Biology major, Undergraduate class of 2007; Medical school class of 2012.

2) **Gordon LB.** Brown University Undergraduate Student Mentor to Elaine Tran, 6/15/07-5/31/09, Major/concentration: Neuroscience major/pre-med track, Undergraduate class of 2009.

3) **Gordon LB.** Brown University Undergraduate Student Mentor to Tamara Cameo, 9/15/09-5/31/12, Major/concentration: Major in Biology/pre-med track
Undergraduate class of 2012.

4) **Gordon LB.** Brown University Undergraduate Student Mentor to Eleanor DiBiasio, 5/15/2010-5/31/13, Major/concentration: Major in Community Health, Undergraduate class of 2013; Completed MPH at Brown in 2014, Alpert Medical School class of 2019.

5) **Gordon LB.** Brown University Undergraduate Student Mentor to Meghal Shah, 9/22/13-5/31/14, Major/concentration: Neuroscience major/pre-med track, Undergraduate class of 2014.

6) **Gordon LB.** Brown University Undergraduate Student Mentor to Angelica Johnsen, Projected 2/13/15 – 2020, Major/concentration: Plans to major in Neuroscience/premed; Undergraduate class of 2019.

OTHER TEACHING ROLES:

1) **Gordon LB.** Student Forum on Hutchinson Gilford Progeria Syndrome, Biological Sciences 50, Genetics and Genomics, Harvard University, Boston, MA, May 2004.

2) **Gordon LB.** Guest lecturer, Hutchinson-Gilford Progeria Syndrome: A New Avenue for Cardiovascular and Aging Research through Rare Disease Discoveries. Stem Cells and Regeneration in Disease Pathobiology and Treatment, Human Development and Regenerative Biology, Harvard Medical School, Boston, MA, Mar 2011.

3) **Gordon LB.** Guest lecturer, Hutchinson-Gilford Progeria Syndrome: A New Avenue for Cardiovascular and Aging Research through Rare Disease Discoveries. Stem Cells and Regeneration in Disease Pathobiology and Treatment, Human Development and Regenerative Biology, Harvard Medical School, Boston, MA, Apr 2012.

4) **Gordon LB.** Boston University, Master's Student Practicum Supervisor to Alyssa Biller, Course number PH975, Spring Semester, 2015.

DISEASE PUBLIC AWARENESS ACTIVITIES:

FILM WITH ACCOMPANYING ONLINE DIGITAL / PRINT ARTICLES:

1) NBC News – *Today* | Interview: Dr. Scott Berns and Dr. Leslie Gordon of the Progeria Research Foundation discuss the discovery of the gene responsible for the disease; April 24, 2003

2) CNN - *Live at Daybreak* | Paging Dr. Gupta: Look at Rare Genetic Disorder; April 24, 2003

3) ABC News - *Primetime* | Progeria Parents Struggle to Find Cure for Rare Terminal Disease; October 15, 2003

4) ABC News | Rapidly Aging Kids; August 8, 2006

5) *60 Minutes* | Progeria; June 24, 2007

6) The Dr. Oz Show | Progeria and the Mysteries of Aging; March 5, 2010

7) CNN | Clues found in mysterious childhood aging disease; September 10, 2010

8) CNN | Advances in kids' early aging disease; September 25, 2012

9) ABC News 20/20 | Progeria: Drug Raises Hope for Rapid-Aging Disease; September 26, 2012

10) ABC News – 20/20 | Making Lemonade; January 18, 2013

11) Katie Couric Show | 16-Year-old with Progeria An Inspiration to All; October 9, 2013

12) HBO full length documentary | Life According to Sam; Premiere date October 21, 2013

13) ABC News | The Triumphant Story of Sam Berns, Progeria and Math; October 21, 2013

14) News Nation Now | 1st drug for rare rapid-aging disease extends kids' lives; November 21, 2020

15) American University–Cairo YouTube documentary on Progeria: "Zein, Child of Happiness," | December 22, 2020

PRINT/DIGITAL:

1) *The New York Times* | On Rare Diseases, Parents Take Hope Into Their Own Hands; November 17, 2003

2) Reuters | Doctor's sick child spurs medical breakthrough; April 15, 2003

3) *The Boston Globe* | Gene Work May Help Treat Aging Child Illness Drove Research by Tufts Doctor; April 16, 2003

4) *USA Today* | Aging disorder gene revealed; Discovery boosts hope for progeria patients; April 16, 2003

5) *Boston Herald* | Couple inspires scientists to identify progeria gene; April 16, 2003

6) Reuters | Premature aging gene found; April 16, 2003

7) *People* | Old Before His Time; May 3, 2003

8) TIME | Rescuing an ailing child can become a crusade and a career; May 10, 2004

9) *The Times Magazine* | Racing With Sam; January 30, 2005

10) Associated Press | Family frustrated by lack of cure for daughter; February 4, 2005

11) *The Post-Crescent* | Family scrambles to find cure for disease; July 18, 2005

12) HealthDay | Rare Children's Disease Unlocks Aging's Secrets; July 25, 2005

13) *Los Angeles Times* | Research Shows Drugs Could Block Early-Aging Disease; August 30, 2005

14) HealthDay | Cancer Drugs May Fight Rare Rapid-Aging Disease; September 27, 2005

15) *Pittsburgh Tribune Review* | Findings May Help Treat Aging Disease; July 1, 2006

16) *The Scientist* | DNA damage repair defect unifies theories of aging; December 20, 2006

17) *The Wall Street Journal* | With Just 42 Known Cases, Drug Trial Is Delicate Task; January 29, 2007

18) *The Globe and Mail* | Unlocking clues to the mystery of aging; February 7, 2008

19) *Scientific American* | New Hope for Progeria: Drug for Rare Aging Disease; October 10, 2008

20) *Brown Medicine* | For Ourselves and Others; Winter 2008

21) *The Scientist* | Progeria Effort Pays Off; Ivan Oransky

22) Express Pharma | Reversing a chromosomal error; May 15, 2010

23) Today at Brown | Questions For…Leslie Gordon: Progeria learns from aging; aging learns from progeria; December 7, 2010

24) *The Washington Post* | *A* New Drug for Rare, Fatal Childhood Disease?; June 29, 2011

25) *The Boston Globe* | New hope in fight against rare aging disorder; June 29, 2011

26) *New Scientist* | Experts hope that a rare genetic disease may help explain common aging processes; July 19, 2011

27) *The Wall Street Journal* | Drug Shows Promise for Rapid Aging Kids; September 24, 2012

28) *Science* | Progeria Trial Gets Mixed Reviews; September 24, 2012

29) *The Boston Globe* | Children with progeria, who age prematurely, show modest improvement in; Boston drug trial; September 25, 2012

30) *Brown Daily Herald* | First clinical trial offers hope for progeria patients; September 26, 2012

31) *The New York Times Magazine* | Revisiting Sam Berns; October 2, 2012

32) *The Philadelphia Inquirer* | Parents race with time as sons age prematurely; October 8, 2012

33) Wall Street Journal *Lunch Break* | Hope for Children with Rare Aging Disease; November 25, 2012

34) *Science News* | Rare disease sets mom's research agenda; February 7, 2013

35) *The Boston Globe* | A pediatric researcher whose son died of progeria sees promise in new treatment; April, 24, 2018

36) *The Associated Press* | 1st drug for rare rapid-aging disease extends kids' lives; November 20, 2020

37) *The Boston Globe* | FDA approves first drug for rare disease that causes premature aging in children; November 20, 2020

38) *NPR/WBUR* | FDA Approves First Drug For A Rapid Aging Disorder In Children; November 23, 2020*Science News* | The FDA has approved the first drug to treat the rapid-aging disease progeria; November 25, 2020

39) *The Wall Street Journal* | Crispr Gene-Editing Treatment Could Point Way to Fix for Deadly Aging Disease; January 6, 2021

40) *USA Today* | 'A cause for celebration': New gene editing tool offers promise of treating many genetic diseases; January 6, 2021

41) *Science Magazine* | 'Incredible' gene-editing result in mice inspires plans to treat premature-aging syndrome in children; January 6, 2021

42) *Barron's Dow Jones* | A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age | January 6, 2021

43) *STAT News* | The Boston Globe | CRISPR cures progeria in mice, raising hope for one-time therapy for a disease that causes rapid aging; January 6, 2021

44) *Managed Healthcare Executive* | The RNA Moment: Once Second to DNA are Treatments Now Filling the Drug Pipeline; November 9, 2021

45) *The New York Times* | Living With Gusto Despite a Rare, Fatal Disease, and Hunting for Answers; April 1, 2022

46) BS Business Life 360 with Kristi K. | Innovations in Disease Advancement and Management; January 19, 2023

RADIO:

1) KUER | Through the Lens: Life According to Sam; October 30, 2013

2) NPR | Experimental Drug Is First To Help Kids With Premature Aging Disease; September 24, 2012

3) WBUR-Boston *CommonHealth Blog* | First Treatment Found For Rapid-Aging Disease In Children; September 24, 2012

4) NPR | FDA Approves First Drug For A Rapid Aging Disorder In Children; https://www.npr.org/sections/health-shots/2020/11/23/937910370/fda-approves-first-drug-for-a-rapid-aging-disorder-in-children; November 23, 2020

5) Global Genes | Rarecast, Episode 312: How an Ultra-Rare Disease Patient Organization Drove Research to a Treatment; January 10, 2021